{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:08:18Z","timestamp":1784815698812,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014855","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000}}],"reference-count":605,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014855.pub2","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:55:16Z","timestamp":1744106116000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients at high risk of delayed graft function"],"prefix":"10.1002","volume":"2025","author":[{"given":"Laia","family":"Oliveras","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"L\u00f3pez-Vargas","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Melilli","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Codina","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Royuela","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; Biomedical Sciences Research Institute, Hospital Universitario Puerta de Hierro-Majadahonda, CIBERESP; Majadahonda Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Fav\u00e0","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manonelles","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Couceiro","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montero","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat Spain"},{"name":"Biomedical Research Institute (IDIBELL); L'Hospitalet de Llobregat Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0001|cit1","first-page":"570","article-title":"Comparative study of three different patterns of immunosuppression based on induction with basiliximab and low initial doses or delayed initiation of Neoral in kidney transplant recipients at high risk of delayed graft function [abstract no: 1629]","volume":"5","author":"Andres","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-0012.2008.00891.x","article-title":"A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function","volume":"23","author":"Andres","year":"2009","journal-title":"Clinical Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0003|cit3","first-page":"114","article-title":"A randomized study to compare immunosuppression based on basiliximab induction and low initial doses or delayed neoral in kidney transplant recipients at high risk for delayed graft function [abstract no: PO-266]","volume":"18","author":"Marcen","year":"2005","journal-title":"Transplant International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0004|cit4","first-page":"471","article-title":"A phase II, open-label, concentration-controlled, randomized 6-month study of standard-dose tacrolimus + sirolimus + corticosteroids compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1321]","volume":"2","author":"Bechstein","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.transproceed.2013.03.025","article-title":"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients","volume":"45","author":"Bechstein","year":"2013","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0006|cit6","first-page":"785","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus + steroids compared to reduced-dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract no: W379]","volume":"18","author":"Bechstein","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0007|cit7","first-page":"395","article-title":"An open-label, concentration-controlled, randomized, 6-month study of standard-dose tacrolimus + sirolimus + corticosteroids compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]","volume":"2","author":"Cockfield","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0008|cit8","unstructured":"Paczek L Bechstein W Wramner L Squifflet JP A phase II, open-label, concentration-controlled, randomized 6-month study of standard-dose tacrolimus + sirolimus + corticosteroids compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 170] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0009|cit9","first-page":"464","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus +steroids compared to reduced-dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract no: 1219]","volume":"3","author":"Paczek","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0010|cit10","first-page":"464","article-title":"A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus-tacrolimus trials [abstract no: 1218]","volume":"3","author":"Whelchel","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0041-1345(02)03048-8","article-title":"A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients","volume":"34","author":"Charpentier","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD014855.pub2-BIB0013|cit13","first-page":"916A","article-title":"Comparison of ATG induction followed by tacrolimus therapy with ATG induction followed by cyclosporine therapy, and immediate tacrolimus-based triple therapy [abstract no: A4786]","volume":"12","author":"Rostaing","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/01.tp.0000282872.17024.b7","article-title":"Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression","volume":"84","author":"Hernandez","year":"2007","journal-title":"Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD014855.pub2-BIB0015|cit15","first-page":"300A","article-title":"Efficacy and safety of low toxicity (LT) immunosuppressive therapies in renal transplantation (RT) [abstract no: F-PO1074]","volume":"15","author":"Miquel","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0016|cit16","first-page":"466","article-title":"Induction with single bolus ATG or basiliximab in cadaveric kidney transplantation with cyclosporin immunosuppression [abstract no: 2330]","volume":"74","author":"Kyllonen","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyllonen","year":"2007","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.TP.0000128190.08238.A1","article-title":"Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation","volume":"78","author":"Matinlauri","year":"2004","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.tp.0000188175.66835.c6","article-title":"Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations","volume":"80","author":"Matinlauri","year":"2005","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1111\/j.1600-6143.2005.00994.x","article-title":"Activated protein C reduces graft neutrophil activation in clinical renal transplantation","volume":"5","author":"Turunen","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/01.TP.0000122231.43653.CC","article-title":"Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation","volume":"77","author":"Turunen","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0023|cit23","first-page":"464","article-title":"How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]","volume":"5","author":"Budde","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD014855.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1600-6143.2006.01291.x","article-title":"Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study","volume":"6","author":"Kamar","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.transproceed.2007.03.064","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies","volume":"39","author":"Legendre","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0026|cit26","first-page":"464","article-title":"Tolerability of enteric coated mycophenolate sodium (EC-MPS) in combination with Neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]","volume":"5","author":"Legendre","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1399-0012.2007.00660.x","article-title":"Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant","volume":"21","author":"Mourad","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00007890-200407271-01219","article-title":"Assessment of two strategies of neoral\u00ae administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving Myfortic\u00ae, steroids and anti-IL2r antibodies: 6 months interim results [abstract no: P723]","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.transproceed.2004.12.263","article-title":"Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving Myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study","volume":"37","author":"Mourad","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0030|cit30","first-page":"219","article-title":"Assessment of two neoral\u00ae administration strategies on renal function and efficacy in de novo renal transplant patients receiving enteric-coated mycophenolate sodium, steroids and anti-il2r antibodies: 6 months interim analysis of a randomized, multicentre, open, prospective controlled study [abstract no: 224]","volume":"4","author":"Mourad","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0012.2006.00615.x","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials","volume":"21","author":"Pietruck","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0032|cit32","first-page":"A215","article-title":"Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T-PO50030]","volume":"10","author":"Rostaing","year":"2005","journal-title":"Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.transproceed.2006.08.119","article-title":"Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients","volume":"38","author":"Rostaing","year":"2006","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0034|cit34","first-page":"219","article-title":"Safety and tolerability of enteric-coated mycophenolate sodium in combination with steroids and two regimen of Neoral\u00ae, in denovo kidney transplant recipients: 6 months interim results. A randomized, multicentre, open, prospective controlled study [abstract no: 222]","volume":"4","author":"Rostaing","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0035|cit35","first-page":"190","article-title":"Sustainable tolerability effects of Myfortic\u00ae in combination with neoral\u00ae and steroids at 12 months, in de novo kidney transplantation: a randomized, multicentre, open, prospective controlled study [abstract no: 133]","volume":"5","author":"Rostaing","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/ajt.15342","article-title":"Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation","volume":"19","author":"Alloway","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: Five-year follow-up of a randomized study","volume":"15","author":"Hellemans","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"Noel","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0039|cit39","first-page":"233","article-title":"Daclizumab versus thymoglobulin in renal transplant recipients with a high immunological risk: a French and Belgian prospective randomized trial [abstract no: 331]","volume":"7","author":"Noel","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0040|cit40","first-page":"59","article-title":"Outcomes with tacrolimus-based immunosuppression after kidney transplantation with standard-or extended criteria donor organs: the OSAKA study [abstract no: O108]","volume":"26","author":"Albano","year":"2013","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0041|cit41","first-page":"125","article-title":"Safety and renal function in tacrolimus prolonged release vs tacrolimus immediate release-based therapy in renal transplantation \u2013 The OSAKA Study [abstract no: 316]","volume":"11","author":"Albano","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e920041","DOI":"10.12659\/AOT.920041","article-title":"Outcomes with tacrolimus-based immunosuppression after kidney transplantation from standard- and extended-criteria donors - a post hoc analysis of the prospective OSAKA study","volume":"25","author":"Albano","year":"2020","journal-title":"Annals of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0044|cit44","first-page":"125","article-title":"Efficacy and optimised dosing in tacrolimus prolonged release vs tacrolimus immediate release-based therapy in renal transplantation \u2013 The OSAKA Study [abstract no: 317]","volume":"11","author":"Albano","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Abstract","key":"10.1002\/14651858.CD014855.pub2-BIB0045|cit45","first-page":"321A","article-title":"Risk factors for efficacy failure with tacrolimus-based immunosuppression after kidney transplantation \u2013 The OSAKA Study [abstract no: TH-PO908]","volume":"22","author":"Banas","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0046|cit46","first-page":"35","article-title":"Efficacy, safety and optimised dosing in tacrolimus prolonged release vs tacrolimus immediate release-based therapy in renal transplantation - the OSAKA study [abstract no: P064]","volume":"24","author":"Banas","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0047|cit47","first-page":"38","article-title":"Acute rejection in renal transplantation recipients treated with tacrolimus prolonged release-and immediate release-based therapy - The OSAKA study (optimizing immunosuppression after kidney transplantation with Advagraf\u00ae) [abstract no: O-140]","volume":"24","author":"Banas","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0048|cit48","first-page":"39","article-title":"Efficacy and safety of tacrolimus prolonged release and immediate release in de novo renal transplantation - The OSAKA study (optimizing immunosuppression after kidney transplantation with Advagraf\u00ae) [abstract no: O-141]","volume":"24","author":"Kamar","year":"2011","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0049|cit49","first-page":"856A","article-title":"Prolonged-release tacrolimus (QD) is non-inferior to immediate-release (BD) tacrolimus using different measures of clinical efficacy: a combined analysis [abstract no: SA-PO938]","volume":"23","author":"Kramer","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0050|cit50","first-page":"164","article-title":"Influence of donor related factors on outcomes with tacrolimus-based immunosuppression after kidney transplantation - The OSAKA study (optimizing immunosuppression after kidney transplantation with Advagraf\u00ae) [abstract no: RO-126]","volume":"24","author":"Lehner","year":"2011","journal-title":"Transplant International"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/TP.0b013e3181ba06ee","article-title":"A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration","volume":"88","author":"Andres","year":"2009","journal-title":"Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy Is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/bjs.4976","article-title":"Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants","volume":"92","author":"Wilson","year":"2005","journal-title":"British Journal of Surgery"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00007890-201407151-00472","article-title":"Results of a large randomized controlled trial of alemtuzumab-versus basiliximab-based induction therapy in kidney transplantation [abstract no: 2986]","volume":"98","author":"Haynes","year":"2014","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1432-2277.2006.00280.x","article-title":"Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation","volume":"19","author":"Alexander","year":"2006","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0056|cit56","first-page":"792","article-title":"Early steroid withdrawal or tacrolimus minimization versus standard immunosuppression in renal transplant recipients: the ALLEGRO trial","volume":"18","author":"Sanders","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1097\/TXD.0000000000000794","article-title":"Early steroid withdrawal compared with standard immunosuppression in kidney transplantation - interim analysis of the Amsterdam-Leiden-Groningen randomized controlled trial","volume":"4","author":"Sandwijk","year":"2018","journal-title":"Transplantation Direct"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/TP.0000000000004776","article-title":"Comparison of 2 immunosuppression minimization strategies in kidney transplantation: the ALLEGRO Trial","volume":"108","author":"den Born","year":"2024","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007890-201407151-00448","article-title":"Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial","volume":"98","author":"Arns","year":"2014","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0060|cit60","first-page":"857A","article-title":"APOLLO after 4 years: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: SA-PO1003]","volume":"24","author":"Arns","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study","volume":"83","author":"Budde","year":"2015","journal-title":"Clinical Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0062|cit62","first-page":"464A","article-title":"5 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal tranplant recipients [abstract no: FR-PO407]","volume":"25","author":"Budde","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0063|cit63","first-page":"411","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year data of the APOLLO trial [abstract]","volume":"11","author":"Budde","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl S3","key":"10.1002\/14651858.CD014855.pub2-BIB0064|cit64","first-page":"298","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]","volume":"12","author":"Budde","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40620-014-0134-4","article-title":"Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial","volume":"28","author":"Budde","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0066|cit66","first-page":"311","article-title":"Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract]","volume":"13","author":"Budde","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0067|cit67","first-page":"504","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]","volume":"10","author":"Budde","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0068|cit68","first-page":"iii259","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]","volume":"3","author":"Haller","year":"2010","journal-title":"NDT Plus"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00007890-201007272-01167","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients one year after conversion [abstract]","volume":"90","author":"Rath","year":"2010","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0070|cit70","first-page":"50","article-title":"Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract]","volume":"24","author":"Reinke","year":"2011","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0071|cit71","first-page":"340A","article-title":"Results of the APOLLO trial: renal function of an everolimus based therapy after 3 years of calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: TH-PO1040]","volume":"23","author":"Reinke","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0072|cit72","first-page":"240","article-title":"Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]","volume":"26","author":"Rhat","year":"2013","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0073|cit73","first-page":"804A","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients one year after conversion [abstract no: SA-PO3036]","volume":"21","author":"Sommerer","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0074|cit74","first-page":"180","article-title":"Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow-up data of the APOLLO trial [abstract]","volume":"24","author":"Sommerer","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0075|cit75","first-page":"21","article-title":"4 Year data of the APOLLO trial: Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]","volume":"26","author":"Sommerer","year":"2013","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0076|cit76","first-page":"172","article-title":"Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P-309]","volume":"22","author":"Holdaas","year":"2009","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/01.tp.0000331151.41142.6c","article-title":"Assessment of everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: 1646]","volume":"86","author":"Holdaas","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00007890-201007272-00642","article-title":"Long-term post transplantation switch to an everolimus-based therapy with CNI elimination\/minimization does not overall impact graft function: The ASCERTAIN study [abstract]","volume":"90","author":"Holdaas","year":"2010","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0080|cit80","unstructured":"O'Connell P Fassett R Pilmore H Chapman J Hutchison B Russ G Long-term post transplantation switch to an everolimus-based therapy with CNI elimination\/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting 2011 June 29-Jul 1, Canberra, ACT 2011 42"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0081|cit81","unstructured":"O'Connell P Fassett R Pilmore H Chapman J Hutchison B Russ G Post-hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting 2011 June 29-Jul 1, Canberra, ACT 2011 41 CN-01707377"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00007890-201007272-01835","article-title":"Post-hoc analysis of the ASCERTAIN trial indicate that everolimus based therapy with CNI elimination improves renal function in select populations [abstract]","volume":"90","author":"O'Connell","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0083|cit83","first-page":"44","article-title":"Risk factor analysis for renal function outcome in maintenance renal transplant recipients from the ASCERTAIN study [abstract]","volume":"11","author":"Rostaing","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0084|cit84","first-page":"811A","article-title":"Everolimus ASCERTAIN: multivariate analyses identified high baseline GFR as a major factor for improving renal function [abstract no: SA-PO3067]","volume":"21","author":"Rostaing","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000365671","article-title":"A prospective randomised paired trial of sirolimus versus tacrolimus as primary immunosuppression following non-heart beating donor kidney transplantation","volume":"7","author":"Asher","year":"2014","journal-title":"Current Urology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0086|cit86","unstructured":"Wyrley-Birch H Kanwar A Dakshinamoorty V Navarro A Reddy M Asher J A prospective randomised paired trial of sirolimus versus tacrolimus as primary immunosuppression following non heart beating donor kidney transplantation [abstract no: O41] British Transplantation Society (BTS).13th Annual Congress; 2010 Mar 17-19; Kensington, UK 2010"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0087|cit87","first-page":"239","article-title":"Early results from a trial comparing sirolimus with tacrolimus as primary immunosuppression for recipients of non heart beating donor (NHBD) kidneys after anti-IL2 monoclonal antibody [abstract no: P-580]","volume":"22","author":"Wyrley-Birch","year":"2009","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1097\/TXD.0000000000000877","article-title":"Safety and efficacy of reduced prolonged-release tacrolimus exposure in de novo kidney transplantation: a randomized, open-label, pilot study in Asia-OPTIMIZE study","volume":"5","author":"Kim","year":"2019","journal-title":"Transplantation Direct"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00007890-201007272-01187","article-title":"Clinically better renal function with everolimus and very low tacrolimus exposure in de novo renal transplant recipients at 12 months: the ASSET Study [abstract no: 1555]","volume":"90","author":"Christiaans","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0090|cit90","first-page":"151","article-title":"Everolimus and very low exposure of tacrolimus provides good efficacy in de novo renal transplant recipients (RTxR) at 12 months [abstract no: 375]","volume":"10","author":"Christiaans","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00007890-201007272-00211","article-title":"Efficacy benefit with everolimus and very low tacrolimus exposure in de novo renal transplant recipients: 12 month results of the ASSET Study [abstract no: 1549]","volume":"90","author":"Hene","year":"2010","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0092|cit92","first-page":"809A","article-title":"Everolimus with low or very low exposure of tacrolimus preserves renal function with good efficacy in de novo renal transplant recipients: the ASSET study [abstract no: SA-PO3066]","volume":"20","author":"Langer","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0094|cit94","first-page":"502","article-title":"Preservation of renal function with everolimus and very low tacrolimus exposure in de novo renal transplant recipients (RTxR) at 12 months: the ASSET Study [abstract no: 1633]","volume":"10","author":"Pascual","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00007890-201007272-00817","article-title":"Effects of everolimus with very low tacrolimus exposure on the incidence of NODM after renal transplantation in the ASSET Study [abstract no: 1295]","volume":"90","author":"Pascual","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0096|cit96","first-page":"299","article-title":"Pharmacokinetics of everolimus when combined with tacrolimus: results from the ASSET study in de novo renal transplant recipients [abstract no: 931]","volume":"12","author":"Pascual","year":"2012","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12659\/AOT.890673","article-title":"The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study","volume":"19","author":"Rostaing","year":"2014","journal-title":"Annals of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0098|cit98","first-page":"253","article-title":"Pharmacokinetics of everolimus when combined with tacrolimus in de novo renal transplant recipients [abstract]","volume":"24","author":"Rostaing","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0099|cit99","first-page":"53","article-title":"Everolimus with low or very low exposure of tacrolimus in de novo renal transplant recipients: the ASSET study [abstract no: O-201]","volume":"22","author":"Vitko","year":"2009","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1264903","DOI":"10.3389\/frtra.2023.1264903","article-title":"Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study","volume":"2","author":"Arns","year":"2023","journal-title":"Frontiers in Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0101|cit101","first-page":"810","article-title":"Everolimus [EVR]-based versus tacrolimus[TAC]-MPA regimen in de novo kidney transplant recipients: 12 months safety and efficacy data from the ATHENA study [abstract no: SA-PO510]","volume":"28","author":"Dragun","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0102|cit102","first-page":"562","article-title":"ATHENA study outcomes on allograft function after 12 months with everolimus-CNI vs tacrolimus-MPA regimen in de novo renal transplant recipients [abstract]","volume":"30","author":"Dragun","year":"2017","journal-title":"Transplant International"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1097\/01.tp.0000542744.74545.40","article-title":"Significant anti-CMV\/BKV effect of a modern everolimus-based regimen compared to standard tacrolimus-MPA regimen in De novo kidney transplant recipients: ATHENA 12 months data on infections [abstract]","volume":"102","author":"Dragun","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0104|cit104","first-page":"318","article-title":"Significant anti-CMV\/BKV effect of a modern everolimus-based regimen comparted to a standard tacrolimus-MPA regimen in de novo kidney transplant recipients: ATHENA 12 months data on infections [abstract]","volume":"18","author":"Hauser","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0105|cit105","first-page":"520","article-title":"Differences in CMV-specific CD4 T cell population in de novo kidney transplant recipients treated with everolimus-based regimen compared to a standard tacrolimus-mpa regimen: results from ATHENA [abstract]","volume":"19","author":"Hauser","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0106|cit106","first-page":"803","article-title":"Significantly less CMV-and BKV-events with everolimus-based versus tacrolimus-MPA regimen in de novo renal transplant recipients: 12 months data on infections from the ATHENA study [abstract no: SA-PO484]","volume":"28","author":"Hauser","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0107|cit107","first-page":"14","article-title":"12 months data on infections from ATHENA study show significantly less CMV-and BKV-events with everolimus-based versus tacrolimus-MPA regimen in de novo renal transplant recipients [abstract]","volume":"31","author":"Kamar","year":"2018","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0108|cit108","first-page":"25","article-title":"12 months safety and efficacy data from ATHENA study on everolimus-based vs tacrolimus-MPA regimen in de novo kidney transplant recipients [abstract]","volume":"31","author":"Kamar","year":"2018","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0109|cit109","first-page":"15","article-title":"12 months outcomes on allograft function with everolimus-CNI vs tacrolimus-MPA regimen in de novo renal transplant recipients: the ATHENA study [abstract]","volume":"31","author":"Merville","year":"2018","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0110|cit110","first-page":"162","article-title":"Significantly less CMV-and BKV-events with everolimus-based vs. tacrolimus-MPA regimen in de novo renal transplant recipients: 12 months data on infections from ATHENA study [abstract]","volume":"30","author":"Nashan","year":"2017","journal-title":"Transplant International"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1097\/01.tp.0000542975.38490.c5","article-title":"The ATHENA study: 12 months safety and efficacy data for everolimus combined with tacrolimus or cyclosporine compared to a standard tacrolimus-mycophenolate regimen in de novo kidney transplant patients [abstract]","volume":"102","author":"Nashan","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0112|cit112","first-page":"260","article-title":"Allograft function after 12 months with everolimus plus either tacrolimus or cyclosporine compared to a standard regimen of tacrolimus with mpa in de novo renal transplant recipients: the ATHENA study [abstract]","volume":"18","author":"Nashan","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1097\/01.tp.0000542977.46114.31","article-title":"Outcomes on allograft function after 12 months with everolimus plus either tacrolimus or cyclosporine compared to a standard tacrolimus-MPA regimen in de novo renal transplant recipients: the ATHENA study [abstract]","volume":"102","author":"Schenker","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0114|cit114","first-page":"450","article-title":"12-month ATHENA study: Everolimus versus standard regimen in de novo renal transplant recipients [abstract]","volume":"28","author":"Sommerer","year":"2015","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0115|cit115","first-page":"160","article-title":"Everolimus-based vs. tacrolimus-MPA regimen in de novo kidney transplant recipients: 12 months safety and efficacy data from ATHENA study [abstract]","volume":"30","author":"Sommerer","year":"2017","journal-title":"Transplant International"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0116|cit116","first-page":"92","article-title":"Design and rationale of the ATHENA study - a 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial","volume":"17","author":"Sommerer","year":"2016","journal-title":"Trials [Electronic Resource]"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0117|cit117","first-page":"20","article-title":"ATHENA study: outcomes on allograft function after 12 months of modern everolimus-based vs. conservative tacrolimus-MPA regimen in de novo renal transplant recipients [abstract]","volume":"30","author":"Sommerer","year":"2017","journal-title":"Transplant International"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0119|cit119","first-page":"15","article-title":"Reduced incidence of CMV-events with modern everolimus-based vs conservative tacrolimus-MPA-based regimen in de novo renal transplant recipients: 12 months data on infections from ATHENA study [abstract]","volume":"30","author":"Suwelack","year":"2017","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0120|cit120","first-page":"259","article-title":"The ATHENA study: 12 months safety and efficacy data from everolimus combined with tacrolimus or cyclosporine compared to a standard tacrolimus-mycophenolate regimen in de novo kidney transplant patients [abstract]","volume":"18","author":"Suwelack","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0121|cit121","first-page":"18","article-title":"European kidney transplant trial ATHENA-patient and allograft outcome by country [abstract]","volume":"31","author":"Thaiss","year":"2018","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0122|cit122","first-page":"20","article-title":"12 months data from ATHENA study show comparable safety and efficacy of modern everolimus-based regimen vs. conservative tacrolimus-MPA-based regimen in de novo renal transplant recipients [abstract]","volume":"30","author":"Thaiss","year":"2017","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0123|cit123","first-page":"614a","article-title":"Design and rationale of ATHENA study:a 12-month study evaluating everolimus versus standard regimen in de novo renal transplant recipients-baseline data [abstract no: FR-PO1067]","volume":"26","author":"Thaiss","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0124|cit124","first-page":"57","article-title":"ATHENA study outcomes on allograft function after 12 months with everolimus-based versus tacrolimus-MPA regimen in de novo renal transplant recipients [abstract no: FR-OR078]","volume":"28","author":"Thaiss","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40246-015-0059-6","article-title":"Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery","volume":"10","author":"Azevedo","year":"2016","journal-title":"Human Genomics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0126|cit126","first-page":"488","article-title":"The use of urinary retinol binding protein (URBP) as a biomarker for chronic allograft dysfunction: A pilot study [abstract no: 1567]","volume":"12","author":"Chinen","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0127|cit127","first-page":"337A","article-title":"Immunosupression individualization can ameliorates early tubular dysfunction in renal transplanted patients with improvement in renal function over time [abstract no: TH-PO989]","volume":"20","author":"Chinen","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/01.TP.0000063703.32564.3B","article-title":"A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients","volume":"75","author":"Baboolal","year":"2003","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"927-8","DOI":"10.1111\/ajt.16171","article-title":"Clinical study of standard versus reduced dose tacrolimus combined with generic mycophenolate mofetil in de novo kidney transplantation [abstract]","volume":"20","author":"Bang","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.transproceed.2019.11.029","article-title":"Clinical study of standard- vs reduced-dose tacrolimus combined with generic mycophenolate mofetil in de novo kidney transplantation: a prospective randomized trial","volume":"52","author":"Bang","year":"2020","journal-title":"Transplantation Proceedings"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0131|cit131","first-page":"234A","article-title":"Triple therapy with neoral, steroids and enteric-coated mycophenolate acid vs everolimus: efficacy, side effects and pharmaco-economic aspects. A monocentric experience [abstract no: F-PO614]","volume":"18","author":"Bertoni","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0132|cit132","first-page":"112","article-title":"Cyclosporine very low dose with everolimus high dose is associated with excellent outcomes in renal transplant patients [abstract]","volume":"24","author":"Bertoni","year":"2011","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0133|cit133","first-page":"800A","article-title":"Everolimus (E) vs enteric coated mycophenolate sodium (EC-MPS): proteomic and pathologic aspects [abstract no: SA-PO3020]","volume":"21","author":"Bertoni","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0134|cit134","first-page":"91","article-title":"Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M) [abstract no: LB-1]","volume":"22","author":"Bertoni","year":"2009","journal-title":"Transplant International"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.5301\/JN.2011.6247","article-title":"Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients","volume":"24","author":"Bertoni","year":"2011","journal-title":"Journal of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00007890-201007272-00559","article-title":"Cyclosporine (CYA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS [abstract]","volume":"90","author":"Bertoni","year":"2010","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0137|cit137","first-page":"818A","article-title":"Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment [abstract no: SA-PO3100]","volume":"20","author":"Bertoni","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0138|cit138","first-page":"102A","article-title":"Cyclosporine (CYA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M) [abstract no: SA-FC449]","volume":"21","author":"Bertoni","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD014855.pub2-BIB0139|cit139","first-page":"vi396","article-title":"Triple therapy with neoral, steroids and enteric-coated mycophenolic acid vs everolimus: efficacy, side effects and pharmaco-economic aspects. A monocentric experience [abstract no: SaP477]","volume":"22","author":"Rosati","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00007890-201007272-00794","article-title":"Everolimus(E) vs enteric coated mycophenolate sodium (EC-MPS): Proteomic and pathologic aspects in a 1-year prospective randomized study [abstract]","volume":"90","author":"Salvadori","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0141|cit141","first-page":"221","article-title":"MTOR inhibition diminishes peripheral blood CD8+CD28-CD38hi effector\/memory T cells and facilitates resolution of belatacept-refractory kidney rejection [abstract]","volume":"17","author":"Castro-Rojas","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0142|cit142","first-page":"958","article-title":"Belatacept-refractory CD8+CD28-CD38hi effector\/memory T cells are targeted by mTOR inhibition leading to a preferential loss of CD40L [abstract]","volume":"18","author":"Godarova","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/TP.0000000000002917","article-title":"mTOR inhibitor therapy diminishes circulating CD8+ CD28- effector memory T cells and improves allograft inflammation in belatacept-refractory renal allograft rejection","volume":"104","author":"Castro-Rojas","year":"2020","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0144|cit144","first-page":"511","article-title":"Five-year follow-up from a prospective, randomized trial of belatacept-based, CNI free\/early steroid withdrawal regimens [abstract]","volume":"22","author":"Hames","year":"2022","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0145|cit145","first-page":"449","article-title":"A prospective randomized multicenter trial (BEST trial) of belatacept-based C N I-and corticosteroid-free immunosuppression: final two year results [abstract]","volume":"19","author":"Kaufman","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0147|cit147","first-page":"418","article-title":"Patient-reported outcomes in a prospective multicenter trial of belatacept-based CNI-and corticosteroid-free immunosuppression regimens in kidney transplantation [abstract]","volume":"19","author":"Rohan","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0148|cit148","first-page":"365","article-title":"Belatacept based simultaneous calcineurin inhibitor avoidance\/early corticosteroid withdrawal is associated with low new onset diabetes risk [abstract]","volume":"19","author":"Shields","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0149|cit149","first-page":"953","article-title":"A prospective, randomized, multicenter trial of bela-based CNI free and steroid withdrawal immunosuppression: BEST trial two year characterization of rejection and renal function [abstract]","volume":"19","author":"Wiseman","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0150|cit150","first-page":"541","article-title":"The BEST trial: A prospective randomized trial of belatacept-based, CNI-and corticosteroid-free immunosuppression [abstract]","volume":"16","author":"Woodle","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0151|cit151","first-page":"290","article-title":"The BEST trial: a prospective randomized multicenter trial of belatacept-based CNI- and corticosteroid-free immunosuppression [abstract]","volume":"18","author":"Woodle","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0153|cit153","first-page":"190","article-title":"A phase 2 study to assess the safety and efficacy of alefacept (ALEF) in de novo kidney transplant recipients [abstract]","volume":"11","author":"Bromberg","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0154|cit154","first-page":"70","article-title":"A phase 2 study to assess the safety and efficacy of alefacept (ALEF) in de novo kidney transplant recipients [abstract]","volume":"24","author":"Cibrik","year":"2011","journal-title":"Transplant International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00007890-200407271-00225","article-title":"Safety and efficacy of reduced or full dose of cyclosporine (neoral\u00ae) in combination with mycophenolate sodium (myfortic\u00ae), basiliximab (simulect\u00ae), and steroids in de novo kidney transplant recipients [abstract no: O212]","volume":"78","author":"Budde","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0156|cit156","first-page":"461","article-title":"Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric-coated mycophenolate-sodium, and steroids [abstract no: 1195]","volume":"5","author":"Budde","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CNP67164","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab","volume":"67","author":"Budde","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0158|cit158","first-page":"565A","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab [abstract no: F-PO1088]","volume":"17","author":"Budde","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0159|cit159","first-page":"464","article-title":"How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]","volume":"5","author":"Budde","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.transproceed.2007.03.064","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies","volume":"39","author":"Legendre","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0161|cit161","first-page":"464","article-title":"Tolerability of enteric coated mycophenolate sodium (EC-MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]","volume":"5","author":"Legendre","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0012.2006.00615.x","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials","volume":"21","author":"Pietruck","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0163|cit163","first-page":"A215","article-title":"Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T-PO50030]","volume":"10","author":"Rostaing","year":"2005","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.transproceed.2012.07.142","article-title":"High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study","volume":"44","author":"Burkhalter","year":"2012","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 167","key":"10.1002\/14651858.CD014855.pub2-BIB0165|cit165","first-page":"15S","article-title":"An open, single centre, prospective study to investigate a steroid free immunosuppressive regimen for de novo renal transplant recipients followed by a two arm randomisation to a CNI-sparing and a CNI-free maintenance immunosuppression after 3 months [abstract no: 38]","volume":"138","author":"Oettl","year":"2008","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0166|cit166","unstructured":"Ekberg H Grinyo J Nashan B Vanrenterghem Y Vincenti F CAESAR Study Group Low-dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract no: 93] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego (CA) 2004"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00007890-200407271-01230","article-title":"The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract no: P734]","volume":"78","author":"Ekberg","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0169|cit169","first-page":"410","article-title":"Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]","volume":"6","author":"Grinyo","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200948050-00005","article-title":"Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients","volume":"48","author":"Kuypers","year":"2009","journal-title":"Clinical Pharmacokinetics"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0171|cit171","first-page":"539","article-title":"The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose\/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results [abstract no: 1507]","volume":"5","author":"Vincenti","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 181","key":"10.1002\/14651858.CD014855.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ijcp.12403","article-title":"A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients","volume":"68","author":"Cai","year":"2014","journal-title":"International Journal of Clinical Practice Supplement"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.transproceed.2008.07.085","article-title":"Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up","volume":"40","author":"Munoz","year":"2008","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0174|cit174","first-page":"406","article-title":"CAMPSIA: a pilot randomised controlled trial of the effectiveness of campath-1h (mabcampath\u00ae) as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: 908]","volume":"4","author":"Vathsala","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0175|cit175","first-page":"224A","article-title":"Induction therapy with alemtuzumab together with low dose cyclosporine monotherapy permits steroid-free immunosuppression, mitigates drug-related, non-immune toxicities and improves quality of life [abstract no: TH-PO550]","volume":"17","author":"Vathsala","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0176|cit176","first-page":"415","article-title":"Lymphocyte recovery after depletion by alemtuzumab in renal transplant recipients: impact on outcome [abstract no: 1015]","volume":"5","author":"Vathsala","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007890-200407271-00158","article-title":"Safety and efficacy of campath-1h (mabcampath\u00ae) with low dose cyclosprorine monotherapy in patients receiving kidney transplants - 6 month analysis of the pilot randomised controlled [abstract no: O145]","volume":"78","author":"Vathsala","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0179|cit179","first-page":"A215","article-title":"One year results of a pilot randomised controlled trial of the effectiveness of alemtuzumab as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: T-PO50029]","volume":"10","author":"Vathsala","year":"2005","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0180|cit180","unstructured":"Chadban S Campbell S Russ G Walker R Chapman J Pussell B A one-year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric-coated mycophenolate sodium (EC-MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA-ME), basiliximab and steroids in de novo kidney transplantation [abstract no: 32] Transplantation Society of Australia & New Zealand (TSANZ). 24th Annual Scientific Meeting; 2006 Mar 29-31; Canberra (ACT) 2006 51"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/nep.12004","article-title":"Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients","volume":"18","author":"Chadban","year":"2013","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0183|cit183","first-page":"678A","article-title":"Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA-PO2529]","volume":"19","author":"Chan","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":"Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0185|cit185","first-page":"217","article-title":"Randomized, multicenter study of the safety and efficacy of enteric-coated mycophenolate sodium combined with basiliximab and low or standard dose of tacrolimus in de novo renal transplant patients [abstract no: 507]","volume":"20","author":"Andres","year":"2007","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0186|cit186","unstructured":"Asderakis A Chan L Renal function with enteric-coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6-month study in de novo renal transplant recipients [abstract no: O111] British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21-24; Liverpool, UK 2009"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"941640","DOI":"10.1155\/2012\/941640","article-title":"Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC-MPS","volume":"2012","author":"Chan","year":"2012","journal-title":"Journal of Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD014855.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.tp.0000332102.57699.c5","article-title":"Renal function and incidence of NODM with enteric-coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6-month comparative study in de novo renal transplant recipients [abstract no: 718]","volume":"86","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0189|cit189","unstructured":"Nicholson ML Chan L Incidence of new onset diabetes mellitus in de novo renal transplant recipients treated with enteric-coated mycophenolate sodium in combination with reduced or standard tacrolimus target levels: Results of a 6-month randomized study [abstract no: P266] British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21-24; Liverpool, UK 2009"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0190|cit190","first-page":"829A","article-title":"Treatment of high-risk renal transplant recipients with EC-MPS (Myfortic\u00ae) is safe and efficacious [abstract no: PUB216]","volume":"16","author":"Bresnahan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0191|cit191","first-page":"464","article-title":"How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]","volume":"5","author":"Budde","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0192|cit192","first-page":"190","article-title":"Safety and efficacy of EC-MPS in combination with simulect and neoral in de novo renal transplant high-risk recipients [abstract no: 135]","volume":"5","author":"Cibrik","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0193|cit193","first-page":"218","article-title":"Enteric-coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]","volume":"4","author":"Cibrik","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1399-0012.2006.00622.x","article-title":"Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients","volume":"21","author":"Cibrik","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.transproceed.2007.03.064","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies","volume":"39","author":"Legendre","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0196|cit196","first-page":"464","article-title":"Tolerability of enteric coated mycophenolate sodium (EC-MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]","volume":"5","author":"Legendre","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD014855.pub2-BIB0197|cit197","first-page":"299A","article-title":"Optimized Neoral C2 monitoring in combination with enteric-coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12-month results of a multicenter, randomized, prospective trial. [abstract no: F-PO1068]","volume":"15","author":"Meier-Kriesche","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0012.2006.00615.x","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials","volume":"21","author":"Pietruck","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0199|cit199","first-page":"A215","article-title":"Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T-PO50030]","volume":"10","author":"Rostaing","year":"2005","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/TP.0000000000001973","article-title":"Improved pulse wave velocity and renal function in individualized calcineurin-inhibitor treatment by immunomonitoring: the randomized controlled Calcineurin Inhibitor-Sparing (CIS) Trial","volume":"102","author":"Sommerer","year":"2018","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0201|cit201","first-page":"617A","article-title":"Monitoring of ciclosporin by NFAT-regulated gene expression reduces the cardiovascular risk- the CIS trial [abstract no: FR-PO1077]","volume":"26","author":"Sommerer","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0202|cit202","first-page":"489","article-title":"The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial","volume":"15","author":"Sommerer","year":"2014","journal-title":"Trials [Electronic Resource]"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00007890-201407151-02329","article-title":"Standard vs. low dose extended-release tacrolimus (Advagraf) in de novo renal transplant: 6-month interim analysis [abstract]","volume":"98","author":"Cockfield","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0204|cit204","first-page":"231","article-title":"Impact of antihypertensive (AHT) choice and Advagraf dose on interstitial fibrosis\/tubular atrophy (IF\/TA) and IF\/TA progression in renal allografts 24 months post-transplantation (Tx) [abstract]","volume":"17","author":"Cockfield","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/ajt.15225","article-title":"Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi\/ARB on the histology and function of renal allografts","volume":"19","author":"Cockfield","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0206|cit206","first-page":"231","article-title":"Impact of antihypertensive (AHT) choice and Advagraf dose on immunologic events in renal allografts 24 months post-transplantation (Tx) [abstract]","volume":"17","author":"Rush","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0207|cit207","first-page":"966","article-title":"Long-term impact of antihypertensive treatment and tacrolimus dose in renal allograft recipients 5 years post-transplantation [abstract]","volume":"19","author":"Rush","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0208|cit208","first-page":"1755","article-title":"Design and baseline characteristics of CRADLE: A study evaluating the efficacy and safety of everolimus to reduce CNI exposure and to withdraw steroids in pediatric renal transplant recipients [abstract no: P226]","volume":"29","author":"Christian","year":"2014","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0209|cit209","first-page":"407","article-title":"Efficacy and safety of everolimus with reduced-exposure tacrolimus and corticosteroid withdrawal in de novo pediatric renal transplant recipients: 12-month results from the CRADLE study [abstract]","volume":"17","author":"Ettenger","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0210|cit210","first-page":"328","article-title":"Design of a randomized study evaluating everolimus in pediatric renal transplant recipients [abstract no: P708]","volume":"26","author":"Gupta","year":"2013","journal-title":"Transplant International"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0211|cit211","first-page":"1712","article-title":"Rationale, design and baseline characteristics of pediatric renal transplant recipients in CRADLE study: a randomised study to evaluate the effect of early everolimus initiation to reduce calcineurin inhibitor exposure and to withdraw steroid [abstract]","volume":"30","author":"Pape","year":"2015","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0212|cit212","first-page":"1816","article-title":"Rationale and design of a study evaluating the efficacy and safety of early conversion of calcineurin inhibitor to everolimus in paediatric renal transplant recipients [abstract no: P376]","volume":"27","author":"Strologo","year":"2012","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0213|cit213","first-page":"1","article-title":"Renal function outcomes of everolimus with reduced-dose tacrolimus and corticosteroid withdrawal-based regimen in de novo pediatric renal transplant recipients: 12-month analysis of the CRADLE study [abstract]","volume":"21","author":"Tedesco","year":"2017","journal-title":"Pediatric Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0214|cit214","first-page":"374","article-title":"Effect of everolimus with reduced-exposure tacrolimus and early steroid elimination in pediatric kidney transplant recipients: 36-month outcomes from the CRADLE study [abstract no: 135]","volume":"19","author":"Tedesco Silva","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0215|cit215","first-page":"1","article-title":"Efficacy and safety of everolimus with reduced tacrolimus and early steroid elimination regimen in de novo pediatric renal transplant recipients: 12-month data from the CRADLE study [abstract]","volume":"21","author":"Tonshoff","year":"2017","journal-title":"Pediatric Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0216|cit216","first-page":"22","article-title":"Preservation of renal function with everolimus plus reduced tacrolimus and corticosteroid withdrawal-based regimen in de novo pediatric renal transplant recipients: 12-months results: the CRADLE study [abstract]","volume":"30","author":"Tonshoff","year":"2017","journal-title":"Transplant International"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ajt.15081","article-title":"Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: results of a randomized trial","volume":"19","author":"Tonshoff","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0218|cit218","first-page":"402","article-title":"Baseline characteristics of CRADLE study evaluating the effect of early everolimus initiation to reduce calcineurin inhibitor exposure and to withdraw steroid in pediatric renal transplant recipients [abstract]","volume":"28","author":"Tonshoff","year":"2015","journal-title":"Transplant International"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0219|cit219","first-page":"1798","article-title":"Preservation of renal function with everolimus plus reduced-dose tacrolimus and corticosteroid withdrawal-based regimen in de novo pediatric renal transplant recipients: 12-month results from the CRADLE study [abstract no: P-372]","volume":"32","author":"Tonshoff","year":"2017","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0220|cit220","first-page":"328","article-title":"Design of CRAD001A2314: a randomised study evaluating everolimus in paediatric renal transplantation [abstract no: P712]","volume":"26","author":"Tonshoff","year":"2013","journal-title":"Transplant International"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0221|cit221","first-page":"1924","article-title":"Randomized trial on everolimus in pediatric renal transplantation: three-year data of the CRADLE study [abstract no: IPN10673-88]","volume":"34","author":"Tonshoff","year":"2019","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00007890-201407151-01841","article-title":"A randomized, prospective study comparing everolimus\/low tacrolimus with regular tacrolimus\/MPS for the elderly renal transplant recipients [abstract]","volume":"98","author":"David-Neto","year":"2014","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD014855.pub2-BIB0223|cit223","first-page":"699A","article-title":"The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]","volume":"9","author":"Smak Gregoor","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1681\/ASN.V1281750","article-title":"A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids","volume":"12","author":"Sevaux","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0225|cit225","unstructured":"de Sevaux RG Smak Gregoor PJ Hene RJ Hoitsma AJ Vos P Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome, Italy 2000"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1097\/00007890-199806270-00437","article-title":"A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]","volume":"65","author":"S\u00e9vaux","year":"1998","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1093\/ndt\/gfq135","article-title":"A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits","volume":"25","author":"Etienne","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0228|cit228","first-page":"410","article-title":"Impact of two years of 50% reduction of cyclosporine exposure in stable kidney transplant recipients treated with mycophenolate mofetil without corticosteroids on renal function: Results at 60 months of follow-up of a multicenter randomized controlled trial: The DICAM study [abstract]","volume":"11","author":"Etienne","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0229|cit229","first-page":"124","article-title":"A randomized trial comparing standard everolimus plus cyclosporine with higher blood everolimus levels plus very low cyclosporine levels in renal transplant recipients: preliminary results of the Everest Study [abstract no: P118]","volume":"20","author":"Citterio","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.tp.0000332261.21413.8a","article-title":"Exposure to everolimus, and not to cyclosporine, is associated with freedom from acute rejection in de novo renal recipients [abstract no: 447]","volume":"86","author":"Corbetta","year":"2008","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/TP.0b013e318216c1db","article-title":"Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study","volume":"91","author":"Ponticelli","year":"2011","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.tp.0000332262.59531.35","article-title":"Targeting upper everolimus blood levels with very low-dose cyclosporine is effective and safe in de novo renal transplantation [abstract no: 448]","volume":"86","author":"Salvadori","year":"2008","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0234|cit234","first-page":"497","article-title":"Upper everolimus blood levels with very low-dose cyclosporin: 12 months follow up of the Everest Study [abstract no: 1085]","volume":"9","author":"Salvadori","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0235|cit235","first-page":"185","article-title":"Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation - impact on renal function and rejection episodes [abstract no: 113]","volume":"5","author":"Fangmann","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0236|cit236","first-page":"353","article-title":"Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]","volume":"4","author":"Fangmann","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00007890-200407271-00744","article-title":"Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]","volume":"78","author":"Fangmann","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfp468","article-title":"Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation","volume":"25","author":"Fangmann","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0239|cit239","unstructured":"Ferguson R Mulgaonkar S Tedesco Silva H Oppenheimer F Walker R FTY720 with reduced-exposure (R-E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract] Transplantation Society of Australia & New Zealand (TSANZ). 21st Annual Scientific Meeting; 2003 Apr 9-11; Canberra (ACT) 2003 63"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0240|cit240","unstructured":"Ferguson RM Mulgaonkar S Tedesco H Oppenheimer F Walker R Kunzendor U FTY720 with reduced-exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0241|cit241","first-page":"311","article-title":"High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12-month preliminary results [abstract no: 624]","volume":"3","author":"Ferguson","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/j.1600-6143.2006.01404.x","article-title":"FTY720\/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study","volume":"6","author":"Mulgaonkar","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0243|cit243","first-page":"432","article-title":"FTY720 with reduced dose Neoral (RDN) may offer a safety\/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]","volume":"4","author":"Russ","year":"2004","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0244|cit244","unstructured":"Walker R Eris J Russ G FTY121 International Study Group FTY720 with reduced cyclosporine exposure (RCE) prevents rejection in renal transplantation (TRX): 12-month (m) preliminary results [abstract no: 98] Transplantation Society of Australia & New Zealand (TSANZ). 22nd Annual Scientific Meeting ; 2004 Mar 31-Apr 2; Canberra (ACT) 2004 87"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0245|cit245","first-page":"499","article-title":"FTY720 with reduced cyclosporine exposure is efficacious in preventing rejection in renal transplantation: 12-month preliminary results [abstract no: T680]","volume":"18","author":"Walker","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0246|cit246","first-page":"D140","article-title":"mTOR-based CNI minimization vs withdrawal in African American kidney transplant recipients [abstract]","volume":"15","author":"Fleming","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/ctr.12718","article-title":"A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients","volume":"30","author":"Fleming","year":"2016","journal-title":"Clinical Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0248|cit248","first-page":"190","article-title":"Low dose immunosuppression is not sufficient to avoid acute rejections in old for old kidney transplant recipients: a one year prospective multicenter randomized controlled trial [abstract no: P-384]","volume":"22","author":"Fricke","year":"2009","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0249|cit249","first-page":"498","article-title":"Low does tacrolimus versus mycophenolate-mofetil in \"old for old\" kidney transplantation: a one year prospective multicenter randomized controlled trial [abstract no: 1090]","volume":"9","author":"Meier","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/jrpp.JRPP_17_90","article-title":"Comparing the effect of immediate versus delayed initiation of tacrolimus on delayed graft function in kidney transplant recipients: a randomized open-label clinical trial","volume":"7","author":"Ghadimi","year":"2018","journal-title":"Journal of Research in Pharmacy Practice"},{"issue":"Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0251|cit251","first-page":"A216","article-title":"Mycophenolate mofetil (MMF) plus low dose versus high dose cyclosporine A (CSA) induction protocols in renal transplantation [abstract no: T-PO50034]","volume":"10","author":"Ghafari","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0252|cit252","first-page":"iv265","article-title":"Early low dose versus high dose cyclosporine A (CSA) induction protocols in renal transplantation [abstract no: SP742]","volume":"21","author":"Ghafari","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.transproceed.2007.03.014","article-title":"Low-dose versus high-dose cyclosporine induction protocols in renal transplantation","volume":"39","author":"Ghafari","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/ajt.14897","article-title":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy","volume":"18","author":"Sommerer","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0255|cit255","unstructured":"Comparing the starting time of tacrolimus administration in management of kidney transplant recipients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT201604253043N11 2016"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0256|cit256","first-page":"461","article-title":"12 month results of a phase III prospective, randomised study to evaluate concentration controlled rapamune with cyclosporin dose minimization or eliminiation in de novo renal allograft recipient [abstract no: 1206]","volume":"3","author":"Jardine","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0257|cit257","first-page":"286","article-title":"Phase III prospective, randomized study to evaluate the safety and efficacy of concentration controlled rapamune (sirolimus) with ciclosporin dose minimisation or elimination in de novo renal allograft recipients at 12 months [abstract no: 464]","volume":"4","author":"Jardine","year":"2004","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0258|cit258","unstructured":"Jindal RM UK and Ireland Rapamune Study Group A phase III prospective, randomised study to evaluate concentration controlled rapamune with cyclosporin dose minimization or elimination at six months in de novo renal allograft recipients [abstract no: 0436] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0259|cit259","first-page":"78","article-title":"Improvement in renal function following conversion from low-dose mycophenolate acid to higher-dose enteric-coated mycophenolate sodium (EC-MPS) with concomitant tacrolimus reduction in maintenance kidney transplant recipients [abstract no: O-295]","volume":"22","author":"Kamar","year":"2009","journal-title":"Transplant International"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CN107227","article-title":"A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients","volume":"77","author":"Kamar","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3349\/ymj.2017.58.1.217","article-title":"Cyclosporine sparing effect of enteric-coated mycophenolate sodium in de novo kidney transplantation","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Medical Journal"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0262|cit262","first-page":"374","article-title":"Cyclosporine sparing effect of entericcoated mycophenolate sodium in de novo kidney transplantation [abstract]","volume":"28","author":"Oh","year":"2015","journal-title":"Transplant International"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.transproceed.2007.03.072","article-title":"Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy","volume":"39","author":"Liu","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0264|cit264","first-page":"274","article-title":"Defining the optimal doses of sirolimus and tacrolimus in high-risk cadaveric renal transplant recipients [abstract no: 541]","volume":"2","author":"Gaber","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0266|cit266","first-page":"460","article-title":"Comparison of two different rapamycin based immunosuppressive regimens in cadaveric renal transplantation [abstract no: 1205]","volume":"3","author":"Lo","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1016\/S0041-1345(03)00238-0","article-title":"Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients","volume":"35","author":"Lo","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","article-title":"Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation","volume":"18","author":"Lo","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0269|cit269","first-page":"544","article-title":"The use of sirolimus and mycophenolate mofetil is associated with improved renal function, but similar metabolic profiles to sirolimus and tacrolimus [abstract]","volume":"4","author":"Lo","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1016\/j.transproceed.2010.09.065","article-title":"Cyclosporine and mycophenolate mofetil 48 hours before renal transplantation enables the use of low cyclosporine doses and achieves better graft function","volume":"42","author":"Maamoun","year":"2010","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.tp.0000235545.49391.1b","article-title":"Sirolimus interferes with iron homeostasis in renal transplant recipients","volume":"82","author":"Maiorano","year":"2006","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0273|cit273","first-page":"234","article-title":"Alemtuzumab (Campath-1H) induction followed by tacrolimus monotherapy vs tacrolimus based triple drug immunosuppression in cadaveric renal transplantation - results of a multicenter trial [abstract no: 333]","volume":"7","author":"Margreiter","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0274|cit274","first-page":"508","article-title":"Five-year follow-up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]","volume":"10","author":"David-Neto","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0275|cit275","first-page":"278","article-title":"Interim analysis of the MODIFY study in renal transplantation [abstract no: P243]","volume":"78","author":"David-Neto","year":"2004","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0276|cit276","first-page":"278","article-title":"Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract no: P242]","volume":"78","author":"David-Neto","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0277|cit277","first-page":"234","article-title":"Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract no: 279]","volume":"4","author":"David-Neto","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0278|cit278","first-page":"255","article-title":"Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract no: 353]","volume":"4","author":"David-Neto","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"355","DOI":"10.6061\/clinics\/2012(04)09","article-title":"The impact of pretransplant donor-specific antibodies on graft outcome in renal transplantation: a six-year follow-up study","volume":"67","author":"David-Neto","year":"2012","journal-title":"Clinics"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014855.pub2-BIB0280|cit280","first-page":"466","article-title":"The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract no: 1216]","volume":"5","author":"Pereira","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0281|cit281","first-page":"84","article-title":"A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1-year result of the MODIFY study [abstract no: 53]","volume":"6","author":"Pereira","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0282|cit282","first-page":"465","article-title":"An open-label study to evaluate the efficacy & safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 1224]","volume":"3","author":"Muehlbacher","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/tri.12228","article-title":"The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study","volume":"27","author":"Muhlbacher","year":"2014","journal-title":"Transplant International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0284|cit284","first-page":"238","article-title":"An open-label study to evaluate the efficacy & safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 399]","volume":"2","author":"Muhlbacher","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0285|cit285","unstructured":"Neumayer H Muhlbacher F Stefoni S Del Castillo D Myfortic Maintenance Renal Transplantation Study Group An open-label study to evaluate the efficacy & safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0286|cit286","first-page":"785","article-title":"An open-label study to evaluate the efficacy & safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: W738]","volume":"18","author":"Neumayer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0287|cit287","first-page":"299","article-title":"RAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine [abstract no: 516]","volume":"1","author":"Curtis","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0288|cit288","first-page":"474","article-title":"One year result of a multicenter, open-label trial on safety and efficacy of certican (RAD) used in combination with simulect, corticosteroids, and full or reduced dose neoral in renal transplant [abstract no: 1335]","volume":"1","author":"Curtis","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD014855.pub2-BIB0289|cit289","first-page":"884A","article-title":"Everolimus (RAD) in combination with reduced dose with reduced dose neoral\u00ae maintains effective immunosuppression with improved tolerability compared to full dose neoral [abstract no: A4625]","volume":"12","author":"Curtis","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0290|cit290","first-page":"685A","article-title":"Multicenter, open-label study of the long-term safety and efficacy of RAD used in combination with simulect, corticosteroids and neoral in renal transplantation (RT): 6 month results [abstract no: A3602)","volume":"11","author":"Curtis","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0291|cit291","unstructured":"Mourad G Boger R Curtis J Nashan B Ponticelli C RAD B 156 Study Group CERTICAN (TM) (RAD; EVEROLIMUS), the proliferation signal inhibitor, is complementary with a reduced dose NEORAL\u00ae based quadruple immunosuppressive regimen [abstract no: 1622] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0292|cit292","unstructured":"Nashan B Curtis J Ponticelli C Mourad G Boger R RAD B 156 Study Group Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose neoral based quadruple immunosuppressive regimen [abstract no: 398] 10th ESOT & 12th ETCO Congress. Bridging the Future; 2001 Oct 6-11; Lisboa, Portugal 2001"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0294|cit294","unstructured":"Ponticelli C Curtis J Kovarik JM Nashan B Mourad G Figueiredo J Everolimus pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine [abstract no: 318] 10th ESOT & 12th ETCO Congress. Bridging the Future; 2001 Oct 6-11; Lisboa, Portugal 2001"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0295|cit295","unstructured":"RADB156 Study Group Boger R Frei U Glotz D Kahan B Ponticelli C CERTICAN(TM) with reduced dose NEORAL\u00ae results in a significantly higher GFR in de novo renal transplant recipients over the first 12 months compared to CERTICAN(TM)-full dose NEORAL\u00ae as assessed by iohexol clearance [abstract no: 1623] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0296|cit296","unstructured":"Study comparing sirolimus\/prograf vs sirolimus\/CsA in high-risk renal transplant recipients https:\/\/clinicaltrials.gov\/show\/NCT00470665 2007"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0297|cit297","unstructured":"Tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil (MMF) versus Neoral\/sirolimus in adult, primary kidney transplantation https:\/\/clinicaltrials.gov\/show\/NCT00681213 2008"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0298|cit298","unstructured":"Comparison between two tacrolimus-based immunosuppressant regimens and induction with thymoglobulin in kidney transplants from deceased donors with expanded criteria https:\/\/clinicaltrials.gov\/show\/NCT01895049 2013"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0299|cit299","unstructured":"Clinical outcome of delayed or standard prograf together with induction therapy followed by conversion to Advagraf in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients https:\/\/clinicaltrials.gov\/show\/NCT03644485 2018"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0300|cit300","first-page":"252","article-title":"Immediate introduction of everolimus does not affect wound healing and delayed graft function in kidney transplant recipients: 12-months results from NEVERWOUND study [abstract]","volume":"20","author":"Carmellini","year":"2017","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00007890-201407151-02082","article-title":"Immediate introduction of everolimus does not affect wound healing and delayed graft function in renal transplant patients: preliminary results from NEVERWOUND study [abstract]","volume":"98","author":"Carmellini","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0302|cit302","first-page":"228","article-title":"Immediate introduction of everolimus does not affect wound healing and delayed graft function in kidney transplant recipients: 3-months results from NEVERWOUND study [abstract]","volume":"16","author":"Carmellini","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/TP.0000000000002851","article-title":"A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early [vs. delayed] introduction of everolimus in de novo kidney transplant recipients, with a follow-up evaluation at 12 month after transplant (NEVERWOUND study)","volume":"104","author":"Manzia","year":"2020","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0304|cit304","first-page":"183","article-title":"Better renal function in renal-transplant recipients treated with everolimus plus CSA elimination compared with CSA reduction [abstract no: P-359]","volume":"22","author":"Grinyo","year":"2009","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0305|cit305","first-page":"503","article-title":"Better renal function in renal-transplant recipients treated with everolimus plus cyclosporine elimination compared with cyclosporine minimisation [abstract no: 1636]","volume":"10","author":"Grinyo","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.transproceed.2011.10.032","article-title":"De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients","volume":"43","author":"Novoa","year":"2011","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4285\/jkstn.2012.26.2.83","article-title":"Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results)","volume":"26","author":"Oh","year":"2012","journal-title":"Journal of the Korean Society for Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/TP.0000000000000225","article-title":"Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine A in de novo kidney recipients","volume":"99","author":"Oh","year":"2015","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.tp.0000331957.34416.f8","article-title":"Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]","volume":"86","author":"Bloom","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0310|cit310","first-page":"228A","article-title":"6-month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH-PO565]","volume":"17","author":"Gaston","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0311|cit311","first-page":"319","article-title":"Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]","volume":"8","author":"Gaston","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the OPTICEPT trial","volume":"9","author":"Gaston","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0313|cit313","first-page":"419","article-title":"Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]","volume":"9","author":"Kaplan","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0b013e3181d18baa","article-title":"Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the OPTICEPT trial","volume":"32","author":"Kaplan","year":"2010","journal-title":"Therapeutic Drug Monitoring"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00007890-201007272-00789","article-title":"Pharmacogenetic factors affecting mycophenolate mofetil (MMF) pharmacokinetic and pharmacodynamic variability in the OPTICEPT kidney transplant study: preliminary analysis [abstract]","volume":"90","author":"Milone","year":"2010","journal-title":"Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0316|cit316","first-page":"96","article-title":"Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU-FC128]","volume":"18","author":"Shaw","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0317|cit317","first-page":"197","article-title":"Optimizing tacrolimus therapy in maintenance renal allografts: 6 month results [abstract no: 390]","volume":"6","author":"Shihab","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD014855.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.tp.0000331135.57350.d3","article-title":"Optimizing tacrolimus therapy in maintenance renal allografts: a single center assessment of cardiovascular risk factors at 36 months [abstract no: 1632]","volume":"86","author":"Bolin","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0319|cit319","first-page":"675A","article-title":"Optimizing tacrolimus therapy in maintenance renal allografts: a single center assessment of cardiovascular risk factors and renal function at 36 months [abstract no: SA-PO2518]","volume":"19","author":"Bolin","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0320|cit320","first-page":"234A","article-title":"Optimizing tacrolimus therapy in maintenance renal allografts: follow up of a subset of patients at 24 months [abstract no: F-PO611]","volume":"18","author":"Bolin","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0321|cit321","first-page":"563A","article-title":"Optimizing tacrolimus therapy in maintenance renal allografts: 6 month results in African Americans (AA) [abstract no: F-PO1077]","volume":"17","author":"Bolin","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0b013e31817442cf","article-title":"Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results","volume":"86","author":"Bolin","year":"2008","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"401","DOI":"10.12659\/AOT.909036","article-title":"Reduced tacrolimus trough level is reflected by estimated glomerular filtration rate (eGFR) changes in stable renal transplantation recipients: results of the OPTIMUM phase 3 randomized controlled study","volume":"23","author":"Park","year":"2018","journal-title":"Annals of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0324|cit324","first-page":"315","article-title":"Organ function preservation by the combination treatment of the optimum dose of calcineurin inhibitor and mycophenolate sodium in kidney recipients: OPTIMUM Study [abstract no: B946]","volume":"13","author":"Park","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0325|cit325","first-page":"316","article-title":"Low dose rabbit anti-thymocyte globulin induction therapy results in prolonged selective CD4 T cell depletion irrespective of maintenance immunosuppression [abstract no: 957]","volume":"10","author":"Pankewycz","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00007890-201007272-00119","article-title":"Low dose rabbit anti-thymocyte globulin induction therapy results in prolonged selective CD4 T cell depletion irrespective of maintenance immunosuppression [abstract]","volume":"90","author":"Pankewycz","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.transproceed.2011.01.034","article-title":"Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression","volume":"43","author":"Pankewycz","year":"2011","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.transproceed.2011.01.033","article-title":"Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study","volume":"43","author":"Pankewycz","year":"2011","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0329|cit329","first-page":"304","article-title":"A protocol biopsy directed randomized trial comparing tacrolimus minimization to sirolimus conversion at 3 months results in an equivalent degree of histological injury at 1 year and equivalent renal function at 2 years [abstract no: 948]","volume":"12","author":"Pankewycz","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0330|cit330","first-page":"448","article-title":"Rabbit anti-thymocyte globulin (rATG) induction therapy followed by tacrolimus conversion to sirolimus at 3 months does not increase Treg cells [abstract no: 1436]","volume":"12","author":"Pankewycz","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0331|cit331","first-page":"509","article-title":"Conversion to low dose tacrolimus or rapamycin 3 months after kidney transplant: a prospective, protocol biopsy guided study [abstract no: 1657]","volume":"10","author":"Pankewycz","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00007890-201007272-00556","article-title":"Conversion to low dose tacrolimus or rapamycin 3 months after kidney transplant: a prospective, protocol biopsy guided study [abstract]","volume":"90","author":"Pankewycz","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","article-title":"Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial","volume":"93","author":"Paoletti","year":"2012","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0334|cit334","first-page":"31","article-title":"Everolimus for regression of left ventricular hypertrophy of renal transplant recipients: a randomized controlled trial [abstract no: 16]","volume":"12","author":"Paoletti","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/01.TP.0000061606.64917.BE","article-title":"A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation","volume":"75","author":"Pascual","year":"2003","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00007890-201407151-01799","article-title":"Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African-American de novo renal transplant recipients [abstract]","volume":"98","author":"Peddi","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00007890-201407151-00249","article-title":"Efficacy and safety of everolimus with low-dose tacrolimus in de novo renal transplant recipients: 12-month randomized study [abstract no: 713]","volume":"98","author":"Qazi","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0339|cit339","first-page":"217","article-title":"Everolimus in combination with reduced dose tacrolimus is effective as a prophylaxis of acute rejection in low-to-moderate immunologic risk de novo kidney transplantation patients [abstract]","volume":"16","author":"Qazi","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00007890-201407151-01819","article-title":"Management of the wound complications in de novo renal transplant recipients: US92 12-month randomized study [abstract]","volume":"98","author":"Shaffer","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00007890-201407151-01806","article-title":"Everolimus-facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract]","volume":"98","author":"Shihab","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0342|cit342","first-page":"732","article-title":"Everolimus does not increase risk of delayed graft function or prolong duration of dialysis in renal transplantation [abstract]","volume":"17","author":"Shihab","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0343|cit343","first-page":"217","article-title":"Relationship between clinical events and everolimus exposure at 12 months in de novo renal transplant recipients [abstract]","volume":"16","author":"Shihab","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0344|cit344","first-page":"544","article-title":"Renal dysfunction at 12 months is not associated with everolimus exposure in de novo renal transplant recipients [abstract]","volume":"16","author":"Shihab","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus","volume":"17","author":"Shihab","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0346|cit346","first-page":"628","article-title":"Post-hoc analysis of everolimus trough levels around the onset of related adverse events and treatment discontinuation in de novo kidney transplant recipients from the US92 study [abstract]","volume":"18","author":"Shihab","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007890-201407151-01803","article-title":"Reduced incidence of CMV and BK virus infection with everolimus vs mycophenolate based regimen in de novo renal transplant recipients [abstract]","volume":"98","author":"Shihab","year":"2014","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0348|cit348","first-page":"734a","article-title":"Everolimus with low-dose tacrolimus versus standard immunosuppressive regimen: subgroup analysis of renal function at 12 months in de novo renal transplant patients [abstract no: SA-PO457]","volume":"27","author":"Shihab","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00007890-201407151-01810","article-title":"Influence of induction therapy on the efficacy of everolimus vs mycophenolate based regimen in de novo renal transplant recipients [abstract]","volume":"98","author":"Vincenti","year":"2014","journal-title":"Transplantation"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0350|cit350","first-page":"S250","article-title":"The effect of everolimus and tacrolimus exposure levels on renal histology parameters 6 months post-transplantation [abstract no: 450.8]","volume":"100","author":"Vincenti","year":"2016","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0351|cit351","first-page":"484","article-title":"The effect of everolimus and tacrolimus exposure levels on renal histology parameters 6 months post-transplantation [abstract]","volume":"16","author":"Yilmaz","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0352|cit352","first-page":"216","article-title":"Everolimus with low-dose tacrolimus vs a standard immunosuppressive regimen: renal histology at 6 months in de novo renal transplant patients [abstract]","volume":"16","author":"Yilmaz","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1111\/j.1600-6143.2006.01535.x","article-title":"Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study","volume":"6","author":"Frimat","year":"2006","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"402750","DOI":"10.1155\/2010\/402750","article-title":"Long-term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: REFERENECE Study 3-year follow up","volume":"2010","author":"Frimat","year":"2010","journal-title":"Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0355|cit355","first-page":"353","article-title":"Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4-year results of a multicenter randomized controlled study. The \"Reference\" study [abstract no: 850]","volume":"6","author":"Kessler","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD014855.pub2-BIB0356|cit356","first-page":"285","article-title":"Renal function evaluation after half dose reduction of Neoral\u00ae in combination with Cellcept\u00ae in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF - REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]","volume":"4","author":"Kessler","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00007890-200407271-00026","article-title":"Renal function evalution after half dose reduction of Neoral\u00ae in combination with Cellcept\u00ae in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF-REFERENCE study: a randomised [abstract no: 013]","volume":"78","author":"Kessler","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0358|cit358","first-page":"350","article-title":"Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal funtion: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]","volume":"3","author":"Kessler","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"September, Prog","key":"10.1002\/14651858.CD014855.pub2-BIB0359|cit359","first-page":"364A","article-title":"The safety and efficacy of reduced- and standard-target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6-month results from Australia [abstract no: SA-P0496]","volume":"13","author":"Russ","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients","volume":"35","author":"Russ","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0361|cit361","first-page":"464","article-title":"A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus-tacrolimus trials [abstract]","volume":"3","author":"Whelchel","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0362|cit362","first-page":"20","article-title":"Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]","volume":"20","author":"Salvadori","year":"2007","journal-title":"Transplant International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/01.tp.0000332650.93005.92","article-title":"Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]","volume":"86","author":"Salvadori","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00007890-200303270-00008","article-title":"The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy","volume":"75","author":"Saunders","year":"2003","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0365|cit365","first-page":"230","article-title":"Molecular profiles of renal allograft biopsies at 12 months post renal transplant in patients exposed to low dose CNI and everolimus vs. patients exposed to full dose CNI and MMF [abstract]","volume":"17","author":"Gallon","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0366|cit366","first-page":"800","article-title":"Long term outcomes of a steroid free, low dose tacrolimus with everolimus regimen in kidney transplant [abstract]","volume":"18","author":"Kassis","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Supp 3","key":"10.1002\/14651858.CD014855.pub2-BIB0367|cit367","article-title":"Prospective study of a steroid free, low dose tacrolimus and everolimus combination regimen in kidney transplant [abstract]","volume":"15","author":"Shetty","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0368|cit368","first-page":"218","article-title":"Impact of low dose tacrolimus with everolimus regimen on renal pathology and t-regulatory cells in kidney transplant [abstract]","volume":"16","author":"Shetty","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0369|cit369","first-page":"535","article-title":"Prospective randomized study of a steroid free, low dose tacrolimus with everolimus regimen in kidney transplant [abstract]","volume":"16","author":"Shetty","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0370|cit370","doi-asserted-by":"publisher","first-page":"i934-5","DOI":"10.1093\/ndt\/gfad063c_4233","article-title":"Fixed low dose versus concentration-controlled initial tacrolimus dosing: Results from a prospective randomized controlled trial (SLOW&LOW STUDY) [abstract]","volume":"38","author":"Stumpf","year":"2023","journal-title":"Nephrology dialysis transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"102381","DOI":"10.1016\/j.eclinm.2023.102381","article-title":"Fixed low dose versus concentration-controlled initial tacrolimus dosing with reduced target levels in the course after kidney transplantation: results from a prospective randomized controlled non-inferiority trial (Slow & Low study)","volume":"67","author":"Stumpf","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1002\/14651858.CD014855.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0373|cit373","first-page":"38A","article-title":"A multicentre RCT of early switch to everolimus plus steroids or everolimus plus CsA versus CsA, MPA and steroids in de novo kidney transplant recipients: 12 month analysis [abstract no: TH-OR155]","volume":"22","author":"Chadban","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0374|cit374","unstructured":"Russ G Eris J Kanellis J Hutchison B Hibberd A Pilmore H Multicentre RCT of early switch to everolimus plus steroids or everolimus plus CSA versus CSA, MPA and steroids in de novo kidney transplant recipients: 12 month analysis [abstract no: 93] Transplantation Society of Australia & New Zealand (TSANZ). 30th Annual Scientific Meeting; 2012 Jun 27-29; Canberra (ACT) 2012 103"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0375|cit375","first-page":"56A","article-title":"Role of rapamycin in the induction of operational tolerance through up-regulation of ILT3 and ILT4 in kidney transplanted patients [abstract no: F-FC248]","volume":"19","author":"Infante","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","article-title":"Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients","volume":"16","author":"Stallone","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0377|cit377","first-page":"869A","article-title":"Sirolimus (SRL) induces ILT3 high ILT4 high dendritic cells (DC) promoting a new immunoregolatory pathway [abstract no: SA-PO993]","volume":"23","author":"Stallone","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2013.337","article-title":"Rapamycin induces ILT3(high)ILT4(high) dendritic cells promoting a new immunoregulatory pathway","volume":"85","author":"Stallone","year":"2014","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00007890-201407151-00282","article-title":"A randomized 2X2 factorial trial: part 1, single-dose rATG induction improves long-term renal transplant outcomes [abstract]","volume":"98","author":"Stevens","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00007890-201407151-01586","article-title":"A randomized trial of renal transplantation: steroid and calcineurin-inhibitor withdrawal after rabbit anti-thymocyte globulin induction [abstract]","volume":"98","author":"Stevens","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0381|cit381","first-page":"209","article-title":"Significantly reduced renal allograft histopathology after single-dose rATG induction and calcineurin-inhibitor withdrawal vs. minimization: Final report from a prospective, randomized clinical trial [abstract]","volume":"11","author":"Stevens","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"e0139247","DOI":"10.1371\/journal.pone.0139247","article-title":"A randomized 2x2 factorial clinical trial of renal transplantation: steroid-free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology","volume":"10","author":"Stevens","year":"2015","journal-title":"PLoS One [Electronic Resource]"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/TP.0000000000000250","article-title":"A randomized 2x2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes","volume":"99","author":"Stevens","year":"2015","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0384|cit384","first-page":"49","article-title":"Reduced patient mortality and infectious complications, and superior graft function, in renal transplant patients after single-dose RATG induction; 5-year data from a prospective, randomized trial [abstract no: 38]","volume":"10","author":"Stevens","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1399-0012.2011.01425.x","article-title":"Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia","volume":"26","author":"Stevens","year":"2012","journal-title":"Clinical Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0386|cit386","first-page":"522","article-title":"Single-dose rabbit anti-thymocyte globulin (rATG) induction reduces tubular injury after renal transplantation, resulting in superior renal function, serum Mg++ retention, and glucose regulation [abstract no: 1703]","volume":"10","author":"Stevens","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0387|cit387","first-page":"322","article-title":"Single-dose induction with rabbit anti-thymocyte globulin (rATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no: 538]","volume":"8","author":"Stevens","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/TP.0b013e3181722fad","article-title":"Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report","volume":"85","author":"Stevens","year":"2008","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.tp.0000330647.73112.7e","article-title":"Single dose induction with rabbit anti-thymocyte globulin (RATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no: 1960]","volume":"86","author":"Stevens","year":"2008","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/01.tp.0000330827.79456.ba","article-title":"Successful calcineurin-inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients: reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 2123]","volume":"86","author":"Stevens","year":"2008","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0391|cit391","first-page":"369","article-title":"Single-dose induction with rabbit anti-thymocyte globulin (rATG; 6 mg\/kg over 24 hours) is safer and improves immediate and long-term renal allograft function [abstract no: 616]","volume":"9","author":"Stevens","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0392|cit392","first-page":"501","article-title":"Calcineurin-inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients without increase rejection or graft loss [abstract no: 1100]","volume":"9","author":"Stevens","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0393|cit393","first-page":"505","article-title":"Calcineurin-inhibitor withdrawal vs minimization after kidney transplantation is safe but does not improve renal function; 5-year results of a prospective, randomized trail [abstract no: 1643]","volume":"10","author":"Stevens","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0394|cit394","first-page":"255","article-title":"Successful calcineurin-inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients; reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 289]","volume":"8","author":"Stevens","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.transproceed.2008.10.012","article-title":"Modern approaches to combining sirolimus with calcineurin inhibitors","volume":"40","author":"Stevens","year":"2008","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0396|cit396","unstructured":"Bagul A Nicholson M Chavez R Grinyo J Frei U Vanrentergehm Y Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23] British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28-30; Manchester, UK 2007"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0397|cit397","unstructured":"Chavez R Nicholson M Grinyo J Frei U Vanrenterghem Y Daloze P SYMPHONY - Comparing efficacy of standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06] British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28-30; Manchester, UK 2007"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.tp.0000332647.08253.2c","article-title":"Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]","volume":"86","author":"Colom","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0400|cit400","first-page":"563A","article-title":"Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F-PO1078]","volume":"17","author":"Daloze","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD014855.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1432-2277.2009.00937.x","article-title":"Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study","volume":"22","author":"Demirbas","year":"2009","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0402|cit402","first-page":"234","article-title":"Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]","volume":"20","author":"Demirbas","year":"2007","journal-title":"Transplant International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/01.tp.0000331916.77001.c8","article-title":"CNI minimisation with 2 G mycophenolate mofetil - what have we learned from the Symphony Study [abstract no: 964]","volume":"86","author":"Ekberg","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","article-title":"Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study","volume":"25","author":"Ekberg","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0405|cit405","first-page":"160","article-title":"Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0406|cit406","first-page":"235","article-title":"Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]","volume":"20","author":"Ekberg","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0407|cit407","first-page":"161","article-title":"The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0408|cit408","first-page":"320","article-title":"Improved outcomes after de novo renal transplantation: 2-year results from the Symphony Study [abstract no: 531]","volume":"8","author":"Ekberg","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0409|cit409","first-page":"336","article-title":"CNI sparing in de novo renal transplantation: 3-year results from the Symphony Study [abstract no: LB04]","volume":"8","author":"Ekberg","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.tp.0000332146.48976.b4","article-title":"CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3-year results from the Symphony Study [abstract no: 623]","volume":"86","author":"Ekberg","year":"2008","journal-title":"Transplantation"},{"issue":"25","key":"10.1002\/14651858.CD014855.pub2-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0412|cit412","first-page":"83","article-title":"Symphony - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]","volume":"6","author":"Ekberg","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0413|cit413","first-page":"300","article-title":"Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]","volume":"6","author":"Ekberg","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1399-0012.2009.01093.x","article-title":"Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study","volume":"24","author":"Frei","year":"2010","journal-title":"Clinical Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0415|cit415","first-page":"210","article-title":"Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]","volume":"7","author":"Frei","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0416|cit416","first-page":"69A","article-title":"SYMPHONY - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F-FC152]","volume":"17","author":"Frei","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0417|cit417","first-page":"177","article-title":"Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony PK sub-study [abstract no: P342]","volume":"20","author":"Grinyo","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0418|cit418","first-page":"345","article-title":"Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]","volume":"6","author":"Grinyo","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0419|cit419","first-page":"443","article-title":"Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony PK sub-study [abstract no: 1151]","volume":"7","author":"Grinyo","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy","volume":"24","author":"Grinyo","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0421|cit421","first-page":"439","article-title":"Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]","volume":"7","author":"Halloran","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0422|cit422","first-page":"186","article-title":"Elderly kidney transplant recipients are a high-risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]","volume":"7","author":"Hugo","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0423|cit423","first-page":"436A","article-title":"Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients - a subgroup analysis of the Symphony Study [abstract no: F-PO1471]","volume":"19","author":"Hugo","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0424|cit424","first-page":"227A","article-title":"Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH-PO564]","volume":"17","author":"Kuypers","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/tri.12018","article-title":"Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study","volume":"26","author":"Llaudo","year":"2013","journal-title":"Transplant International"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0426|cit426","first-page":"220A","article-title":"Influence of MRP2 and UGT1A9 polimorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenonic substudy within the Symphony Study [abstract no: TH-PO508]","volume":"19","author":"Lloberas","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.tp.0000330592.12123.8c","article-title":"Influence of MRP2 and UGT1A9 polimorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]","volume":"86","author":"Lloberas","year":"2008","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/01.tp.0000330593.89252.b9","article-title":"Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]","volume":"86","author":"Lloberas","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD014855.pub2-BIB0429|cit429","first-page":"220A","article-title":"Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH-PO507]","volume":"19","author":"Lloberas","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/ndt\/gfr130","article-title":"Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study","volume":"26","author":"Lloberas","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0431|cit431","first-page":"210","article-title":"Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]","volume":"7","author":"Meier-Kriesche","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0432|cit432","first-page":"234","article-title":"Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]","volume":"20","author":"Meier-Kriesche","year":"2007","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0433|cit433","first-page":"A33","article-title":"Results of the SYMPHONY trial in renal transplantation - comparing standard immunosuppression to low dose cyclosporine (low-CSA), tacrolimus (low-TAC) or sirolimus (low-SRL with MMF, daclizumab and corticosteroids [abstract]","volume":"85","author":"O'Connell","year":"2007","journal-title":"Immunology and Cell Biology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD014855.pub2-BIB0434|cit434","first-page":"228A","article-title":"Health-related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary Results of the Quality of Life Substudy of the Elite Symphony Study [abstract no: TH-PO566]","volume":"17","author":"Oppenheimer","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0435|cit435","first-page":"121","article-title":"Health care resource consumption (HCRC) of patients recieving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]","volume":"20","author":"Oppenheimer","year":"2007","journal-title":"Transplant International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.tp.0000332649.93005.44","article-title":"Cost-effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]","volume":"86","author":"Oppenheimer","year":"2008","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/TP.0b013e31819ec41f","article-title":"Health-related quality of life of patients receiving low-toxicity immunosuppressive regimens: a substudy of the Symphony study","volume":"87","author":"Oppenheimer","year":"2009","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0438|cit438","first-page":"234","article-title":"Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]","volume":"20","author":"Vanrenterghem","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007890-201407151-02101","article-title":"Lower incidence of cytomegalovirus infection with everolimus based immunosuppression versus mycophenolate in de novo renal transplants with 5 years follow-up [abstract]","volume":"98","author":"Goto","year":"2014","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.intimp.2016.07.019","article-title":"5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment","volume":"39","author":"Hiramitsu","year":"2016","journal-title":"International Immunopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0441|cit441","first-page":"474","article-title":"Efficacy and safety of everolimus plus reduced-dose cyclosporine in recipients of living-related and unrelated kidney donors: a 24-month sub-analysis from the A1202 study [abstract]","volume":"30","author":"Nakagawa","year":"2017","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0442|cit442","first-page":"797","article-title":"Long-term efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 9 years follow-up","volume":"18","author":"Narumi","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.transproceed.2019.03.019","article-title":"Everolimus-based immunosuppression possibly suppresses mean fluorescence intensity values of de novo donor-specific antibodies after primary kidney transplantation","volume":"51","author":"Narumi","year":"2019","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007890-201407151-01802","article-title":"Efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 5 years follow-up especially in protocol biopsy findings and donor specific antibody production [abstract]","volume":"98","author":"Narumi","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0445|cit445","first-page":"268","article-title":"Impacts of mycophenolate mofetile addition to very low exposure everolimus and calcineurin inhibitor based immunosuppression in de novo kidney transplantation [abstract]","volume":"28","author":"Narumi","year":"2015","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"i573","DOI":"10.1093\/ndt\/gfw200.27","article-title":"Long-term efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 7 years follow-up [abstract]","volume":"31","author":"Narumi","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl S5","key":"10.1002\/14651858.CD014855.pub2-BIB0447|cit447","first-page":"314","article-title":"Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24-month, randomized, multicenter study [abstract no: B944]","volume":"13","author":"Saito","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0448|cit448","first-page":"300","article-title":"Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de-novo renal transplant patients: 12 month results [abstract no: 935]","volume":"12","author":"Takahara","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplantation Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00007890-201407151-01511","article-title":"Proteinuria and histopathological change of everolimus based immunosuppression on de novo kidney transplantation with 5 years follow-up in protocol biopsies [abstract]","volume":"98","author":"Takeda","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.transproceed.2014.01.010","article-title":"Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients","volume":"46","author":"Uchida","year":"2014","journal-title":"Transplantation Proceedings"},{"issue":"Supp 3","key":"10.1002\/14651858.CD014855.pub2-BIB0452|cit452","article-title":"Everolimus plus reduced-exposure calcineurin inhibitor versus mycophenolate mofetil plus standard-exposure calcineurin inhibitor: 2-year results in living donor kidney transplant recipients [abstract]","volume":"15","author":"Watarai","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0453|cit453","first-page":"iii560","article-title":"Efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 5 years follow-up especially in protocol biopsy findings and donor specific antibody production [abstract]","volume":"29","author":"Watarai","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0454|cit454","first-page":"681","article-title":"Long-term efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 10 years follow up [abstract]","volume":"19","author":"Watarai","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0455|cit455","first-page":"B71","article-title":"Impacts of mycophenolate mofetile addition to very low exposure everolimus and calcineurin inhibitor based immunosuppression in de novo kidney transplantation [abstract]","volume":"15","author":"Watarai","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0456|cit456","first-page":"537","article-title":"Long-term efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 7 years follow-up [abstract]","volume":"16","author":"Watarai","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0457|cit457","first-page":"476","article-title":"Effect of everolimus plus reduced-dose cyclosporine on graft outcomes in kidney transplant recipients with >=3 HLA mismatches: 24-month results from the A1202 study [abstract]","volume":"30","author":"Yoshida","year":"2017","journal-title":"Transplant International"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/ndt\/gfl397","article-title":"Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy","volume":"21","author":"Tang","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0459|cit459","unstructured":"Campbell S Walker R Pilmore H Kanellis J Russ G Hutchison B Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no:43] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29-Jul 1; Canberra (ACT) 2011 64"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0460|cit460","first-page":"209","article-title":"Everolimus de novo with reduced-exposure cyclosporine in renal transplant recipients at high risk of efficacy failure: results of a post-HOC analysis [abstract]","volume":"28","author":"Carmellini","year":"2015","journal-title":"Transplant International"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40620-015-0180-6","article-title":"Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial","volume":"28","author":"Carmellini","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0462|cit462","first-page":"D125","article-title":"Treatment with everolimus and reduced-exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: post-hoc analysis from the A2309 study [abstract]","volume":"15","author":"Carmellini","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0463|cit463","first-page":"57","article-title":"Renal function in renal transplant recipients after 24 months of immunosuppression with concentration-controlled everolimus plus reduced cyclosporine exposure: update from the A2309 study [abstract]","volume":"24","author":"Carmellini","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0464|cit464","first-page":"248","article-title":"Correlation of everolimus exposure with efficacy and safety outcomes in renal transplant recipients: 24-month update [abstract]","volume":"24","author":"Carmellini","year":"2011","journal-title":"Transplant International"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0465|cit465","first-page":"S250","article-title":"Everolimus plus reduced-exposure cyclosporin versus mycophenolic acid plus cyclosporin: Long-term follow-up of Australia and New Zealand kidney transplant recipients in the A2309 randomised controlled trial [abstract no: 450.9]","volume":"100","author":"Chadban","year":"2016","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0466|cit466","first-page":"305","article-title":"Everolimus plus reduced-exposure cyclosporin versus mycophenolic acid plus cyclosporin: Seven-year follow-up of Australia and New Zealand kidney transplant recipients in the A2309 study [abstract]","volume":"16","author":"Chadban","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0467|cit467","first-page":"39","article-title":"Everolimus plus reduced-exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow-up of ANZ patients from a randomised controlled trial [abstract no: 079]","volume":"30","author":"Chadban","year":"2015","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00007890-201007272-00214","article-title":"Correlation of everolimus exposure with efficacy and safety outcomes: Results from a multicenter study in renal transplantation using reduced CsA exposure [abstract]","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00007890-201007272-00558","article-title":"Better renal allograft function with everolimus facilitated CNI reduction-graft type, donor criteria and gender analysis [abstract]","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0470|cit470","first-page":"511","article-title":"Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]","volume":"10","author":"Cibrik","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"S4","key":"10.1002\/14651858.CD014855.pub2-BIB0471|cit471","first-page":"567","article-title":"Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]","volume":"10","author":"Cibrik","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0472|cit472","first-page":"151","article-title":"Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]","volume":"10","author":"Cibrik","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0473|cit473","first-page":"406","article-title":"Renal function stability in renal transplant recipients receiving concentration-controlled everolimus with reduced cyclosporine exposure: 24 month results from the A2309 study [abstract]","volume":"11","author":"Cibrik","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0475|cit475","first-page":"84A","article-title":"Renal function with everolimus plus reduced-dose cyclosporine: Results from a randomized, phase III study [abstract no: SA-FC356]","volume":"20","author":"Cibrik","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5414\/CN108568","article-title":"Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial","volume":"83","author":"Colussi","year":"2015","journal-title":"Clinical Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007890-201407151-01801","article-title":"Different methods for imputing missing renal function data: Evidence from a large clinical trial in renal transplant recipients [abstract]","volume":"98","author":"Dong","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00007890-201407151-01761","article-title":"Changes in the lipid profile in the first year after renal transplantation: Risk factors and influence of immunosuppressive regimens [abstract]","volume":"98","author":"Escrig","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0479|cit479","first-page":"101","article-title":"Donor and recipient factors that influence efficacy outcomes: 12 and 24-month multivariate analyses from kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor [abstract]","volume":"28","author":"Escrig","year":"2015","journal-title":"Transplant International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0480|cit480","first-page":"D126","article-title":"Factors affecting efficacy outcomes at 12 and 24-months after kidney transplantation in patients from the A2309 study [abstract]","volume":"15","author":"Escrig","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0481|cit481","first-page":"858A","article-title":"Surrogate renal function endpoints for predicting long-term allograft survival in kidney transplantation [abstract no: SA-PO1008]","volume":"24","author":"Junge","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0482|cit482","first-page":"570A","article-title":"Gender-matching in renal transplant allograft allocation-does mismatch matter? [abstract no: F-PO2004]","volume":"21","author":"Junge","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0483|cit483","unstructured":"Kanellis J Walker R Pilmore H Russ G Hutchison B Chadban S Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29-Jul 1; Canberra (ACT) 2011 40"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00007890-201007272-00485","article-title":"Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]","volume":"90","author":"Kim","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-201007272-00560","article-title":"60% Reduction in cyclosporine exposure with everolimus over 12 months in de novo renal transplant recipients: Results from a multicenter, randomized study [abstract]","volume":"90","author":"Lackova","year":"2010","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0486|cit486","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney International"},{"issue":"2S","key":"10.1002\/14651858.CD014855.pub2-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.tp.0000331216.10098.6b","article-title":"Lack of variation in serum creatinine values between central study laboratory and Cleveland Clinic in kidney transplant recipients [abstract no: 1565]","volume":"86","author":"Mange","year":"2008","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0488|cit488","unstructured":"Pattison J Riad H Yaqoob M Chan L Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19] British Transplantation Society (BTS).14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK 2011"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0489|cit489","unstructured":"Pattison J Riad H Yaqoob M Tedesco-Silva H Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47] British Transplantation Society (BTS).14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK 2011"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0490|cit490","unstructured":"Pattison J Riad H Yaqoob M Tedesco-Silva H Renal function in de novo kidney transplant patients receiving everolimus with reduced dose ciclosporin or enteric-coated mycophenolic acid with standard-dose ciclosporin: Results from a large-scale, randomised, international trial [abstract no: O36] British Transplantation Society (BTS).13th Annual Congress; 2010 Mar 17-19; Kensington, UK 2010"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0491|cit491","unstructured":"Riad H Pattison J Yaqoob M Chan L 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21] British Transplantation Society (BTS).14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK 2011"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0492|cit492","unstructured":"Riad H Pattison J Yaqoob M Kim YS Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20] British Transplantation Society (BTS).14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK 2011"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0493|cit493","unstructured":"Riad H Pattison J Yaqoob M Tedesco-Silva H Everolimus with reduced-dose ciclosporin as a strategy to optimise long-term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43] British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; Kensington, UK 2010"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0494|cit494","first-page":"A22","article-title":"Everolimus plus reduced-dose cyclosporine: results from a randomized, phase III study in 833 de-novo renal transplant recipients [abstract no: 70]","volume":"88","author":"Russ","year":"2010","journal-title":"Immunology & Cell Biology"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0495|cit495","unstructured":"Russ G Walker R Pilmore H Kanellis J Hutchison B Chadban S Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29-Jul 1; Canberra (ACT) 2011 36"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0496|cit496","unstructured":"Russ G Walker R Pilmore H Kanellis J Hutchison B Chadban S Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70] Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29-Jul 1; Canberra (ACT) 2011 82"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0497|cit497","first-page":"298","article-title":"Exposure-response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]","volume":"12","author":"Shihab","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-201007272-00212","article-title":"De novo everolimus combined with reduced cyclosporine exposure - analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]","volume":"90","author":"Shihab","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-201007272-00212","article-title":"De novo everolimus combined with reduced cyclosporine exposure-analysis of renal function at 12 months in renal transplant recipients","volume":"90","author":"Shihab","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0500|cit500","first-page":"45","article-title":"Lower incidence of cytomegalovirus and BK virus adverse events with everolimus versus mycophenolate was maintained over 24 months in de novo renal transplant recipients [abstract]","volume":"11","author":"Shihab","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clinical Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0502|cit502","first-page":"807A","article-title":"Everolimus plus reduced CsA exposure: preserved efficacy and renal function from 12 to 24 months [abstract no: SA-PO3049]","volume":"21","author":"Shihab","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0503|cit503","first-page":"248","article-title":"Search for new endpoints for clinical trials of immunosuppressive drugs in kidney transplantation [abstract no: P312]","volume":"26","author":"Tedesco-Silva","year":"2013","journal-title":"Transplant International"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.transproceed.2010.02.083","article-title":"Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus","volume":"42","author":"Tedesco-Silva","year":"2010","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0506|cit506","first-page":"509","article-title":"Everolimus-treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-201007272-00213","article-title":"Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]","volume":"90","author":"Tedesco-Silva","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0508|cit508","first-page":"150","article-title":"Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0509|cit509","first-page":"46","article-title":"Concentration-controlled everolimus with reduced cyclosporine concentration in de novo renal transplant recipients: Efficacy results at 24 months [abstract]","volume":"11","author":"Tedesco-Silva","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0510|cit510","first-page":"186","article-title":"Everolimus with reduced-dose cyclosporine as a strategy for optimizing long-term renal function: results from a randomized study in 833 de-novo renal-transplant recipients [abstract no: P-371]","volume":"22","author":"Tedesco-Silva","year":"2009","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.tp.0000332260.21413.c3","article-title":"A randomized, open-label study to compare the safety and efficacy of cyclosporine (CSA) dose reduction with CSA elimination in de novo renal allograft patients receiving sirolimus [abstract no: 446]","volume":"86","author":"Tedesco-Silva","year":"2008","journal-title":"Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0512|cit512","first-page":"84A","article-title":"Everolimus plus reduced-dose cyclosporine: Results from a randomized, phase III study in 833 de-novo renal-transplant recipients [abstract no: SA-FC359]","volume":"20","author":"Tedesco-Silva","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0513|cit513","first-page":"615","article-title":"Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]","volume":"90","author":"Vathsala","year":"2012","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00007890-201007272-01172","article-title":"Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract]","volume":"90","author":"Vathsala","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/00007890-201007272-01163","article-title":"Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]","volume":"90","author":"Walker","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0516|cit516","first-page":"407","article-title":"Class related adverse events in renal transplant recipients treated with everolimus: 24 month results from the A2309 study [abstract]","volume":"11","author":"Walker","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes","volume":"13","author":"Wiseman","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0518|cit518","first-page":"40","article-title":"Cytomegalovirus and BK virus infections are less frequent with everolimus versus mycophenolate immunosuppression: 24-month update from the 2309 study in de novo renal transplant recipients [abstract]","volume":"24","author":"Yaqoob","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0519|cit519","first-page":"39","article-title":"Efficacy and safety of 24 months immunosuppression with concentration controlled everolimus and reduced cyclosporine in de novo renal transplant recipients [abstract]","volume":"24","author":"Yaqoob","year":"2011","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0520|cit520","first-page":"510","article-title":"Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]","volume":"10","author":"Zibari","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0521|cit521","first-page":"897A","article-title":"Incidence of viral infections with everolimus plus reduced-dose cyclosporine: results from a phase III study in 833 de-novo renal-transplant recipients [abstract no: PUB309]","volume":"20","author":"Zibari","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"e052138","DOI":"10.1136\/bmjopen-2021-052138","article-title":"Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study","volume":"11","author":"Aubert","year":"2021","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0523|cit523","first-page":"162","article-title":"TRANSFORM study: Impact of donor type on 12-month outcomes of everolimus and reduced calcineurin inhibitor versus mycophenolate and standard calcineurin inhibitor in de novo kidney transplant patients [abstract]","volume":"30","author":"Berger","year":"2017","journal-title":"Transplant International"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0525|cit525","first-page":"14","article-title":"The TRANSFORM study: lower viral infections with everolimus and reduced calcineurin inhibitor versus mycophenolate and standard calcineurin inhibitor in de novo kidney transplant patients at month 12 [abstract]","volume":"31","author":"Buchler","year":"2018","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0526|cit526","unstructured":"Chadban S Hughes P Campbell S Irish A Lim W O'Connell P TRANSFORM trial design: a randomized, multicentre, open-label study of everolimus with reduced calcineurin inhibitors in over 20000 de novo renal transplant recipients [abstract no:48] Transplantation Society of Australia & New Zealand (TSANZ). 32nd Annual Scientific Meeting; 2014 Jun 11-13; Canberra (ACT) 2014 61"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0527|cit527","first-page":"475","article-title":"Everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplant recipients: efficacy and safety outcomes from the TRANSFORM study [abstract]","volume":"18","author":"Chadban","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0528|cit528","first-page":"357","article-title":"Effcacy and safety outcomes with de novo use of everolimus-based regimen in renal transplant recipients with delayed graft function from the TRANSFORM study [abstract]","volume":"19","author":"Chadban","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0529|cit529","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/14740338.2020.1792441","article-title":"Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study","volume":"19","author":"Citterio","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/01.tp.0000542687.13556.c9","article-title":"Effects of the de novo use of everolimus with reduced calcineurin inhibitor on wound healing events in the TRANSFORM study [abstract]","volume":"102","author":"Citterio","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0531|cit531","first-page":"159","article-title":"The TRANSFORM study: Lower viral infections with everolimus and reduced calcineurin inhibitor versus mycophenolate and standard calcineurin inhibitor in de novo kidney transplant patients at month 12 [abstract]","volume":"30","author":"Cruzado","year":"2017","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0532|cit532","first-page":"759","article-title":"Application of the iBox clinical trial simulation tool to project long-term kidney allograft outcome in the TRANSFORM study [abstract]","volume":"30","author":"Divard","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0533|cit533","first-page":"790","article-title":"Effect of de novo use of everolimus with reduced calcineurin inhibitor versus standard mycophenolic acid-based regimen on wound healing events in kidney transplant recipients from TRANSFORM study [abstract]","volume":"18","author":"Henry","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0534|cit534","first-page":"542","article-title":"TRANSFORM: A modern approach to evaluate long-term outcomes of everolimus with reduced-calcineurin inhibitors in de novo kidney transplant recipients-baseline characteristics [abstract]","volume":"16","author":"Henry","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0535|cit535","first-page":"S725","article-title":"Baseline characteristics of Asian and non-Asian renal transplant recipients: findings from the TRANSFORM trial [abstract no: P.1530]","volume":"100","author":"Lee","year":"2016","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0536|cit536","first-page":"693","article-title":"Assessment of proteinuria reported as adverse events in de novo renal transplant recipients receiving an everolimus-based regimen: 24-month results from TRANSFORM [abstract]","volume":"19","author":"Legendre","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0537|cit537","first-page":"18","article-title":"Efficacy and safety of everolimus [EVR] with reduced-dose calcineurin inhibitor [rCNI] in de novo kidney transplant recipients [KTxRs]: M24 results from the TRANSFORM study [abstract]","volume":"32","author":"Legendre","year":"2019","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0538|cit538","first-page":"14","article-title":"TRANSFORM study: impact of donor type on 12-month outcomes of everolimus and reduced calcineurin inhibitor versus mycophenolate and standard calcineurin inhibitor in De novo kidney transplant patients [abstract]","volume":"31","author":"Legendre","year":"2018","journal-title":"Transplant International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0539|cit539","first-page":"23","article-title":"The TRANSFORM trial design: a large randomized, multicenter, open-label study of everolimus with reduced calcineurin inhibitors in de novo renal transplantation [abstract no: P16]","volume":"26","author":"Legendre","year":"2013","journal-title":"Transplant International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0540|cit540","first-page":"259","article-title":"Effect of everolimus with reduced calcineurin inhibitor on efficacy and safety in de novo kidney transplant recipients: 12-month results from the US cohort of TRANSFORM study [abstract]","volume":"18","author":"Mulgaonkar","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0541|cit541","first-page":"558","article-title":"Effect of induction therapy on outcomes of de novo renal transplant recipients receiving everolimus with reduced-dose calcineurin inhibitor: 24-month results from the TRANSFORM study [abstract]","volume":"19","author":"Oberbauer","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0542|cit542","first-page":"258","article-title":"Everolimus with reduced-dose calcineurin inhibitor versus mycophenolate with standard-dose calcineurin inhibitor in de novo kidney transplant recipients: renal function results from the TRANSFORM study [abstract]","volume":"18","author":"Oppenheimer","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1097\/01.tp.0000543112.91427.9d","article-title":"Renal function outcomes in de novo kidney transplant recipients receiving everolimus with reduced-exposure calcineurin inhibitor versus mycophenolate with standard-exposure calcineurin inhibitor: results from the TRANSFORM study [abstract]","volume":"102","author":"Oppenheimer","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0544|cit544","first-page":"162","article-title":"The TRANSFORM study: effect of everolimus with reduced-exposure calcineurin inhibitor on 12-month renal function outcomes in de novo kidney transplant recipients [abstract]","volume":"30","author":"Oppenheimer","year":"2017","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0545|cit545","first-page":"159","article-title":"The TRANSFORM study: 12-month efficacy and safety of everolimus with reduced calcineurin inhibitor in de novo kidney transplant recipients [abstract]","volume":"30","author":"Pascual","year":"2017","journal-title":"Transplant International"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014855.pub2-BIB0547|cit547","first-page":"247","article-title":"TRANSFORM trial design: effect of everolimus on long-term outcomes after kidney transplantation [abstract no: P308]","volume":"26","author":"Pascual","year":"2013","journal-title":"Transplant International"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1097\/01.tp.0000543119.06675.0b","article-title":"Efficacy and safety of everolimus with reduced-dose calcineurin inhibitor in de novo kidney transplant recipients: results from the TRANSFORM study [abstract]","volume":"102","author":"Pascual","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0549|cit549","first-page":"iii535","article-title":"Balancing efficacy and renal function preservation after kidney transplantation with everolimus and reduced calcineurin inhibitors for better graft outcomes: design of the TRANSFORM study [abstract]","volume":"29","author":"Pascual","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0550|cit550","first-page":"45","article-title":"TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2013","journal-title":"Open Access Journal of Clinical Trials"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OAJCT.S63058","article-title":"TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2014","journal-title":"Open Access Journal of Clinical Trials"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0552|cit552","first-page":"442","article-title":"TRANSFORM: a novel study to evaluate the effect of everolimus with reduced calcineurin inhibitors in de novo kidney transplant recipients: baseline data [abstract]","volume":"28","author":"Pascual","year":"2015","journal-title":"Transplant International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0553|cit553","first-page":"23","article-title":"The TRANSFORM study: infection outcomes with everolimus plus reduced calcineurin inhibitor and mycophenolate plus standard calcineurin inhibitor regimens in de novo kidney transplant recipients [abstract]","volume":"32","author":"Pernin","year":"2019","journal-title":"Transplant International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0554|cit554","first-page":"B6","article-title":"Effect of everolimus with reduced-exposure calcineurin inhibitor in de novo kidney transplant recipients: 24-month results from the US cohort of the TRANSFORM study [abstract no: TH-PO1155]","volume":"29","author":"Qazi","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0555|cit555","first-page":"259","article-title":"Effect of early attainment of everolimus target trough levels on efficacy-safety outcomes in de novo kidney transplant recipients: 12-month results from US92 and TRANSFORM studies [abstract]","volume":"18","author":"Shihab","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1097\/TP.0000000000004555","article-title":"Cardiovascular outcomes in de novo kidney transplant recipients receiving everolimus and reduced calcineurin inhibitor or standard triple therapy: 24-month post hoc analysis from TRANSFORM Study","volume":"107","author":"Sommerer","year":"2023","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0557|cit557","first-page":"742","article-title":"A novel endpoint for evaluating the effect of everolimus with reduced calcineurin inhibitor on long-term kidney graft outcome: the TRANSFORM study protocol [abstract]","volume":"17","author":"Srinivas","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD014855.pub2-BIB0558|cit558","first-page":"976A","article-title":"The TRANSFORM trial design: a large randomized, multicenter, open-label study of everolimus with reduced calcineurin inhibitors in de novo renal transplantation [abstract no: PUB462]","volume":"24","author":"Srinivas","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0559|cit559","first-page":"358","article-title":"Antirejection efficacy in de novo renal transplant recipients receiving everolimus with a reduced-exposure calcineurin inhibitor-based regimen: 24-month results from the TRANSFORM study [abstract]","volume":"19","author":"Tedesco","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD014855.pub2-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014855.pub2-BIB0561|cit561","first-page":"258","article-title":"The TRANSFORM study: infection outcomes with everolimus plus reduced calcineurin inhibitor and mycophenolate plus standard calcineurin inhibitor regimens in de novo kidney transplant recipients [abstract]","volume":"18","author":"Vincenti","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014855.pub2-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1097\/01.tp.0000701884.58397.d2","article-title":"Efficacy and safety of everolimus with reduced calcineurin inhibitor regimen versus mycophenolic acid with standard calcineurin regimen in Asian de novo kidney transplant recipients: two-year results from the subgroup analysis of transform study [abstract]","volume":"104","author":"Watarai","year":"2020","journal-title":"Transplantation"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD014855.pub2-BIB0563|cit563","first-page":"S673","article-title":"TRANSFORM: everolimus with reduced calcineurin inhibitors vs mycophenolate with standard calcineurin inhibitors in de novo kidney transplant recipients-baseline data according to donor type [abstract no: P.1416]","volume":"100","author":"Watarai","year":"2016","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"e14415","DOI":"10.1111\/ctr.14415","article-title":"Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study","volume":"35","author":"Watarai","year":"2021","journal-title":"Clinical Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD014855.pub2-BIB0565|cit565","first-page":"18","article-title":"Everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplant recipients: infection and wound healing outcomes from the TRANSFORM study [abstract]","volume":"31","author":"Witzke","year":"2018","journal-title":"Transplant International"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CM9.0000000000002604","article-title":"A multi-center randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients","volume":"136","author":"Zheng","year":"2023","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0567|cit567","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/CM9.0000000000001866","article-title":"A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients","volume":"25","author":"Zheng","year":"2022","journal-title":"Chinese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12882-021-02409-8","article-title":"Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients","volume":"22","author":"Boer","year":"2021","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MOT.0000000000000604","article-title":"Delayed graft function in kidney transplantation","volume":"24","author":"Bahl","year":"2019","journal-title":"Current Opinion in Organ Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artifical Organs"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0571|cit571","first-page":"853","article-title":"Glomerulotubular function in cyclosporine-treated rats. A lithium clearance, occlusion time\/transit time and micropuncture study","volume":"21","author":"Dieperink","year":"1985","journal-title":"Proceedings of the European Dialysis & Transplant Association - European Renal Association"},{"issue":"25","key":"10.1002\/14651858.CD014855.pub2-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.03850510","article-title":"Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients","volume":"6","author":"Fioretto","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0574|cit574","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1399-0012.2002.1o078.x","article-title":"Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: Use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody","volume":"16","author":"Gonwa","year":"2002","journal-title":"Clinical Transplantation"},{"issue":"7650","key":"10.1002\/14651858.CD014855.pub2-BIB0575|cit575","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"26","key":"10.1002\/14651858.CD014855.pub2-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD014855.pub2-BIB0578|cit578","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0579|cit579","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane (updated August 2024), 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0580|cit580","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/ndt\/gfac165","article-title":"Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study","volume":"38","author":"Huijben","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD014855.pub2-BIB0581|cit581","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2010.03179.x","article-title":"A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation","volume":"10","author":"Irish","year":"2010","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0582|cit582","doi-asserted-by":"crossref","unstructured":"Johansen KL Chertow GM Foley RN Gilbertson DT Herzog CA Ishani A US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States American Journal of Kidney Diseases 2021 77 4 Suppl 1 A7 8 33752804","DOI":"10.1053\/j.ajkd.2021.01.002"},{"issue":"7","key":"10.1002\/14651858.CD014855.pub2-BIB0583|cit583","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006750.pub2","article-title":"Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients","author":"Karpe","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"18409","DOI":"10.1038\/s41598-020-75473-z","article-title":"Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning","volume":"10","author":"Kawakita","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0585|cit585","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9 Suppl 3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0586|cit586","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00007890-200203150-00012","article-title":"Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects","volume":"73","author":"Klein","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0002-9343(90)90429-H","article-title":"Cyclosporine-induced changes in glomerular filtration rate and urea excretion","volume":"88","author":"Laskow","year":"1990","journal-title":"American Journal of Medicine"},{"issue":"9981","key":"10.1002\/14651858.CD014855.pub2-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1053\/j.ajkd.2017.02.003","article-title":"AJKD atlas of renal pathology: calcineurin inhibitor nephrotoxicity","volume":"69","author":"Lusco","year":"2017","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014855.pub2-BIB0590|cit590","first-page":"356","article-title":"The side-effects of ciclosporine-A and tacrolimus","volume":"49","author":"Mihatsch","year":"1998","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/tri.13781","article-title":"The impact of functional delayed graft function in the modern era of kidney transplantation - A retrospective study","volume":"34","author":"Montagud-Marrahi","year":"2021","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0592|cit592","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/TP.0b013e318195a421","article-title":"Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis","volume":"87","author":"Moore","year":"2009","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD014855.pub2-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.1985.196","article-title":"Effect of cyclosporine administration on renal hemodynamics in conscious rats","volume":"28","author":"Murray","year":"1985","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD014855.pub2-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD014855.pub2-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1432-2277.1998.tb00948.x","article-title":"Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506","volume":"11","author":"Radermacher","year":"1998","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0597|cit597","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"2","key":"10.1002\/14651858.CD014855.pub2-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.transproceed.2018.10.022","article-title":"Usefulness of delayed introduction of tacrolimus in kidney transplants using type-III donors after circulatory death","volume":"51","author":"Ruiz-Mart\u00ednez","year":"2019","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0599|cit599","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0600|cit600","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0601|cit601","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1681\/ASN.2010111160","article-title":"Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation","volume":"22","author":"Sharif","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant","volume":"11","author":"Siedlecki","year":"2011","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD014855.pub2-BIB0603|cit603","unstructured":"SONG Handbook Version 1.0 (2017) Available at: www.songinitiative.org\/reports-and-publications\/"},{"issue":"4","key":"10.1002\/14651858.CD014855.pub2-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMoa020274","article-title":"Kidney transplantation from donors without a heartbeat","volume":"347","author":"Weber","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014855.pub2-BIB0605|cit605","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014855","article-title":"Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients","author":"Oliveras","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:33:56Z","timestamp":1784813636000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014855.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":605,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014855.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}